WO2020021061A1 - Anticorps humanisés anti-pd-1 et leurs utilisations - Google Patents

Anticorps humanisés anti-pd-1 et leurs utilisations Download PDF

Info

Publication number
WO2020021061A1
WO2020021061A1 PCT/EP2019/070171 EP2019070171W WO2020021061A1 WO 2020021061 A1 WO2020021061 A1 WO 2020021061A1 EP 2019070171 W EP2019070171 W EP 2019070171W WO 2020021061 A1 WO2020021061 A1 WO 2020021061A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
seq
fragment
nos
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2019/070171
Other languages
English (en)
Inventor
Milan Blanusa
Darragh MACCANN
Sven Berger
Christine Rothe
Shane Olwill
Birgit Bossenmaier
Thomas Jaquin
Eva-Maria HANSBAUER
Christian BARTHELS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pieris Pharmaceuticals GmbH
Original Assignee
Pieris Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals GmbH filed Critical Pieris Pharmaceuticals GmbH
Publication of WO2020021061A1 publication Critical patent/WO2020021061A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Definitions

  • PD-1 programmed cell death protein 1 , or PD-1 (also known as cluster of differentiation 279 or CD279) is a member of the cluster of differentiation 28 (CD28) gene family and is expressed on activated T, B, and myeloid lineage cells (Sharpe et al., Nat Immunol, 2007, Greenwald et al., Annu Rev Immunol, 2005).
  • PD-1 interacts with two ligands, programmed cell death 1 ligand 1 (PD-L1 ) and programmed cell death 1 ligand 2 (PD-L2). Interaction of these ligands with PD-1 plays an important role in downregulating the immune system by limiting overly-active T cells locally, which in turn prevents autoimmunity and maintains peripheral tolerance during infection or inflammation in normal tissues.
  • PD-1 negatively modulates T cell activation, and the inhibitory function of PD-
  • ITIM immunoreceptor tyrosine-based inhibitory motif
  • TILs tumor-infiltrating lymphocytes
  • PD-1/PD-L1 signaling Multiple lines of evidence have indicated that TILs are subject to PD-1 inhibitory regulation and the anti-tumor immunity is modulated by PD-1/PD-L1 signaling.
  • PD-L1 expression has been confirmed in a number of human and mouse tumor lines and that expression can be further upregulated by IFN-g in vitro (Dong et al., Nat Med, 2002).
  • PD-1 inhibitors nivolumab and pembrolizumab
  • PD-1/PD-L1 inhibitors were approved in 2014. Since then, the clinical development of PD-1/PD-L1 inhibitors has rapidly broadened.
  • PD-L1 inhibitors including atezolizumab and avelumab have also been granted FDA approvals.
  • nivolumab also known as ONO-4538, BMS-936558, or MDX1106, marketed as Opdivo®
  • pembrolizumab also referred to as lambrolizumab or MK03475, trade name Keytruda®
  • PDR001 a MEDI0680
  • pidilizumab CT-011
  • ENUM-388D4 including the 388D4-1 , 388D4-2 and 388D4-3 variants
  • ENUM-244C8 including all the variants.
  • provided anti-PD-1 antibodies exhibit diminished non-specific binding as compared to previously known PD-1 antibodies, e.g., humanized 388D4 as described in WO 2016/106159.
  • provided anti-PD-1 antibodies exhibit favorable pharmacokinetic properties as compared to previously known PD-1 antibodies, e.g., humanized 388D4 as described in WO 2016/106159.
  • provided anti-PD-1 antibodies exhibit increased stability and, as a result, improved expression profile as compared to previously known PD-1 antibodies, e.g., humanized 388D4 as described in WO 2016/106159.
  • PD-1 means human PD-1
  • PD-1 includes variants, isoforms, and species homologs of human PD-1.
  • PD-1 is also known as“programmed cell death protein 1”,“cluster of differentiation 279” or“CD279”, which are used interchangeably.
  • Human PD-1 means a full-length protein defined by UniProt Q151 16, a fragment thereof, or a variant thereof. Human PD-1 is encoded by the PDCD1 gene.
  • “antibody” includes whole antibodies and any antigen binding fragment (i.e.,“antigen-binding portion”) or single chain thereof.
  • An“antibody” refers to a glycoprotein comprising at least two heavy chains (HCs) and two light chains (LCs) inter- connected by disulfide bonds, or an antigen binding fragment thereof.
  • Each heavy chain is comprised of a heavy chain variable domain (V H or HCVR) and a heavy chain constant region (C H ).
  • the heavy chain constant region is comprised of three domains, C Hi , C H 2 and C H 3-
  • Each light chain is comprised of a light chain variable domain (V L or LCVR) and a light chain constant region (C L ).
  • the light chain constant region is comprised of one domain, C L .
  • the V H and V L regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs).
  • CDRs complementarity determining regions
  • FRs framework regions
  • Each V H and V L is composed of three CDRs and four FRs, arranged in the following order from the amino-terminus to the carboxy- terminus: FR1 , CDR1 , FR2, CDR2, FR3, CDR3, FR4.
  • the variable regions of the heavy and light chains contain a binding domain that interacts with an antigen (PD-1 in the present case).
  • an“antibody fragment” can be an antigen-binding fragment or a fragment crystallizable region.
  • antigen-binding fragment As used herein, “antigen-binding fragment,” “antigen-binding portion” or
  • antibody-binding domain of an antibody refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., PD-1 ). It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody.
  • an antigen e.g., PD-1
  • binding fragments encompassed within the term “antigen-binding fragment” of an antibody include (i) a Fab fragment consisting of the V H , V L , C L and C Hi domains; (ii) a F(ab') 2 fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fab' fragment comsisting of the V H , V L , C L and C Hi domains and the region between C Hi and C H2 domains; (iv) a Fd fragment consisting of the V H and C Hi domains; (v) a single-chain Fv fragment consisting of the V H and V L domains of a single arm of an antibody, (vi) a dAb fragment (Ward et al., Nature, 1989) consisting of a V H domain; and (vii) an isolated complementarity determining region (CDR) or a combination of two or more isolated CDRs which may optionally be joined by a synthetic linker
  • Antibodies may be polyclonal or monoclonal; xenogeneic, allogeneic, or syngeneic; or modified forms thereof (e.g., humanized, chimeric, multispecific). Antibodies may also be fully human.
  • “framework” or“FR” refers to the variable domain residues other than the hypervariable region (CDR) residues.
  • Fc region refers to the C-terminal region of an immunoglobulin heavy chain, including native-sequence Fc regions and variant Fc regions. Although the boundaries of the Fc region of an immunoglobulin heavy chain might vary, the human IgG heavy-chain Fc region is usually defined to stretch from an amino acid residue at position Cys226, or from Pro230, to the carboxyl-terminus thereof numbering according to EU index of Kabat (Johnson and Wu, Nucleic Acids Res, 2000).
  • the C-terminal lysine (residue 447 according to EU index of Kabat) of the Fc region may be removed, for example, during production or purification of the antibody, or by recombinantly engineering the nucleic acid encoding a heavy chain of the antibody. Accordingly, a composition of intact antibodies may comprise antibody populations with all K447 residues removed, antibody populations with no K447 residues removed, and antibody populations having a mixture of antibodies with and without the K447 residue.
  • Suitable native-sequence Fc regions for use in the antibodies of the invention include human lgG1 , lgG2 (lgG2A, lgG2B), lgG3, and lgG4.
  • Fc receptor or“FcR” refers to a receptor that binds to the Fc region of an antibody.
  • isolated antibody refers to an antibody that is substantially free of its natural environment. For instance, an isolated antibody is substantially free of cellular material and other proteins from the cell or tissue source from which it is derived. An “isolated antibody” further refers to an antibody that is substantially free of other antibodies having different antigenic specificities. In the present case, an isolated antibody that binds specifically PD-1 is substantially free of antibodies that specifically bind antigens other than PD-1. However, an isolated antibody that specifically binds PD-1 may have cross-reactivity to other antigens, such as PD-1 molecules from other species.
  • monoclonal antibody refers to a preparation of antibody molecules of single molecular composition.
  • a monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope.
  • humanized antibody refers to an antibody that consists of the CDR of antibodies derived from mammals other than human, and the FR region and the constant region of a human antibody or derived from a human antibody.
  • a humanized antibody comprises a variable domain that has a variable region amino acid sequence which, analyzed as a whole, is closer to human than to other species as assessed using the Immunogenetics Information System (IMGT) DomainGapAlign tool, as described by Ehrenmann et al. (2010).
  • IMGT Immunogenetics Information System
  • a humanized antibody is useful as an effective component in a therapeutic agent due to the reduce antigenicity.
  • a therapeutic agent may be any agent for the prevention, amelioration, or treatment of a diseases, a physiological condition, a symptom, or for the evaluation or diagnosis thereof.
  • “human antibody” includes antibodies having variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. Furthermore, if the antibody contains a constant region, the constant region is also derived from human germline immunoglobulin sequences.
  • the human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo).
  • the term“human antibody”, as used herein is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
  • binding affinity describes the ability of a biomolecule (e.g., a polypeptide or a protein) of the disclosure (e.g., an antibody) to bind a selected target and form a complex. Binding affinity is measured by a number of methods known to those skilled in the art including, but are not limited to, fluorescence titration, enzyme-linked immunosorbent assay (ELISA)-based assays, including direct and competitive ELISA, calorimetric methods, such as isothermal titration calorimetry (ITC), and surface plasmon resonance (SPR). These methods are well-established in the art and some examples of such methods are further described herein.
  • Binding affinity is thereby reported as a value of dissociation constant ( K d ), half maximal effective concentration (EC 50 ), or half maximal inhibitory concentration (IC 50 ) measured using such these methods.
  • K d dissociation constant
  • EC 50 half maximal effective concentration
  • IC 50 half maximal inhibitory concentration
  • the tearm“about the same,” “substantially the same” or“substantially similar” means one biomolecule has a binding affinity reported as a K d , an EC 50 , or an IC 50 value that is identical or similar to another molecule within the experimental variability of the binding affinity measurement.
  • the experimental variability of the binding affinity measurement is dependent upon the specific method used and is known to those skilled in the art.
  • the term“detect,”“detection,”“detectable,” or“detecting” is understood both on a quantitative and a qualitative level, as well as a combination thereof. It thus includes quantitative, semi-quantitative, and qualitative measurements performed on a biomolecule of the disclosure.
  • detectable affinity generally means the binding ability between a biomolecule and its target, reported by a K d , EC 5 o, or IC 5 o value, is at most about 10 5 M or lower.
  • a binding affinity, reported by a K d , EC 50 , or IC 50 value, higher than 10 5 M is generally no longer measurable with common methods such as ELISA and SPR and is therefore of secondary importance.
  • binding affinity e.g., fluorescence titration, competitive ELISA (also called competition ELISA), and surface plasmon resonance
  • binding affinity reported by a K d , EC 50 , or IC 50 value may vary within a certain experimental range, depending on the method and experimental setup.
  • “specificity,” or“binding specificity” relates to the ability of a biomolecule to discriminate between the desired target (for example, PD-1 ) and one or more reference targets (for example, cytochromes). It is understood that such specificity is not an absolute but a relative property and can be determined, for example, in accordance with SPR, western blots, ELISA, fluorescence activated cell sorting (FACS), radioimmunoassay (RIA), electrochemiluminescence (ECL), immunoradiometric assay (IRMA), ImmunoHistoChemistry (IHC), and peptide scans.
  • FACS fluorescence activated cell sorting
  • RIA radioimmunoassay
  • ECL electrochemiluminescence
  • IRMA immunoradiometric assay
  • IHC ImmunoHistoChemistry
  • the term“specific for,”“specific binding,”“specifically bind,”“specificity,” or“binding specificity” means that the anti-PD-1 antibody binds to, reacts with, or is directed against PD-1 , as described herein, but does not essentially bind another target.
  • the term “another target” includes any proteins or molecules that are not PD-1 or proteins closely related to or being homologous to PD-1.
  • PD-1 from species other than human and fragments and/or variants of PD-1 are not excluded by the term“another target.”
  • the term “does not essentially bind” means that the anti-PD-1 antibody of the present disclosure binds another protein with lower binding affinity than PD-1 , i.e., shows a cross-reactivity of less than 30%, preferably 20%, more preferably 10%, particularly preferably less than 9, 8, 7, 6, or 5%. Whether the anti-PD-1 antibody specifically reacts as defined herein above can easily be tested, inter alia, by comparing the reaction of a anti-PD-1 antibody of the present disclosure with PD-1 and the reaction of said fusion protein with (an)other target(s).
  • the term“off-target” or“off-target binding” as used herein means that a biomolecule does not specifically bind the desired target (e.g., PD-1 ), i.e., the biomolecule cannot discriminate between the desired target and one or more other targets.
  • fragment as used herein with respect to PD-1 relates to N- terminally and/or C-terminally shortened protein or protein domains, which retain the capability of the full-length antigen to be recognized and/or bound by an antibody according to the disclosure.
  • mutagenesis refers to experimental conditions that are chosen such that modifications are introduced into a nucleotide or an amino acid sequences.
  • mutagenesis also includes the (additional) modification of the length of sequence segments by deletion or insertion of one or more amino acids. It is however preferred that mutagenesis does not significally affect or alter the binding characteristics of the antibody encoded by the nucleotide sequence or containing the amino acid sequence.
  • random mutagenesis means that no predetermined single amino acid (mutation) is present at a certain sequence position and mutations can be introduced randomly along all or part of an anti-PD-1 antibody coding sequence.
  • the resulting modified antibodies can be screened for binding specificities and affinities.
  • Identity is a property of sequences that measures their similarity or relationship.
  • sequence identity or“identity” as used in the present disclosure means the percentage of pair-wise identical residues— following (homologous) alignment of a sequence of a polypeptide of the disclosure with a sequence in question— with respect to the number of residues in the longer of these two sequences. Sequence identity is measured by dividing the number of identical amino acid residues by the total number of residues and multiplying the product by 100.
  • the term “homology” is used herein in its usual meaning and includes identical amino acids as well as amino acids which are regarded to be conservative substitutions (for example, exchange of a glutamate residue by an aspartate residue) at equivalent positions in the linear amino acid sequence of a polypeptide of the disclosure (e.g., any lipocalin mutein of the disclosure).
  • the term“substantially” refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest.
  • One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result. Accordingly, the term“substantially” may be used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.
  • the percentage of sequence homology or sequence identity can, for example, be determined herein using the program BLASTP, version blastp 2.2.5 (November 16, 2002) (cf. Altschul et al., Nucleic Acids Res, 1997).
  • the percentage of homology is based on the alignment of the entire polypeptide sequences (matrix: BLOSUM 62; gap costs: 11.1 ; cut-off value set to 10 3 ). It is calculated as the percentage of numbers of “positives” (homologous amino acids) indicated as result in the BLASTP program output divided by the total number of amino acids selected by the program for the alignment.
  • Gaps are spaces in an alignment that are the result of additions or deletions of amino acids. Thus, two copies of exactly the same sequence have 100% identity, but sequences that are less highly conserved, and have deletions, additions, or replacements, may have a lower degree of sequence identity.
  • BLAST Altschul et al., Nucleic Acids Res, 1997)
  • BLAST2 Altschul et al., J Mol Biol, 1990
  • Smith-Waterman Smith and Waterman, J Mol Biol, 1981 .
  • the word“detect”,“detection”,“detectable”, or“detecting” as used herein is understood both on a quantitative and a qualitative level, as well as a combination thereof. It thus includes quantitative, semi-quantitative and qualitative measurements of a molecule of interest.
  • A“subject” is a vertebrate, preferably a mammal, more preferably a human.
  • mammal is used herein to refer to any animal classified as a mammal, including, without limitation, humans, domestic and farm animals, and zoo, sports, or pet animals, such as sheep, dogs, horses, cats, cows, rats, pigs, apes such as cynomolgus monkeys, to name only a few illustrative examples.
  • the“mammal” herein is human.
  • an“effective amount” is an amount sufficient to effect beneficial or desired results.
  • an effective amount of a composition may be one that would be sufficient to enhance or diminish the immune response to a desired level of a therapy.
  • the results of a therapy e.g., activation of a suppressed or deficient immune response, increased cytolytic activity of T cells, increased T cell effector function, alteration of PD-1 activity associated with the negative regulation of T-cell mediated immune response, or reduction in tumor growth
  • An effective amount can be administered in one or more administrations.
  • An effective amount, for example, of a composition can be administered alone, with one additional therapeutic agent, or in combination with two or more additional therapeutic agents.
  • sample is defined as a biological sample taken from any subject.
  • biological samples include blood, serum, urine, feces, semen, or tissue.
  • Figure 1 depicts the results of an enzyme-linked immunosorbent assay
  • Figure 2 depicts the target binding of the humanized PD-1 specific antibodies assessed by flow cytometry using human PD-1 -expressing Flp-ln-CHO cells ( Figure 2A) or cynomolgus PD-1 -expressing Flp-ln-CHO cells ( Figure 2B), as described in Example 5.
  • Figure 3 shows that the humanized PD-1 specific antibodies compete with
  • PD-L1 and PD-L2 for binding to PD-1 depicted in competitive ELISA studies conducted as described in Example 6.
  • a constant concentration of PD-L1-Fc or PD-L2-Fc fusion was coated on a microtiter plate, and a mixture of biotinylated human PD-1-Fc fusion at a constant centration and testing antibodies at different concentrations were titrated.
  • Bound biotinylated PD-1 was detected via Extravidin-HRP.
  • the data was fit with a 1 :1 binding model with IC 50 value and the maximum signal as free parameters, and a slope that was fixed to one.
  • the resulting IC 50 values are provided in Table 5.
  • Figure 4 depicts the results of fluorescence-activated cell sorting (FACS) studies assessing the off-target or non-specific binding of exemplary PD-1 specific antibodies to human endothelial cells (HUVEC) that are PD-1 negative (do not express PD-1 ).
  • the previously known humanized PD-1 antibody with the sequences set forth in SEQ ID NOs: 4 and 9 shows strong, non-specific adhesion to HUVEC cells, while such non-specific adhesion is significantly reduced in humanized PD-1 antibodies provided herein with the sequences set forth in SEQ ID NOs: 58 and 82, SEQ ID NOs: 58 and 83, SEQ ID NOs: 109 and 115, and SEQ ID NOs: 109 and 116.
  • Figure 5 provides the results of a pharmacokinetic analysis of the exemplary humanized PD-1 specific antibodies in mice as described in Example 9.
  • Male CD-1 mice (2 mice per timepoint) were injected intravenously with humanized PD-1 specific antibodiesat a dose of 2 mg/kg.
  • Drug levels were detected using an ELISA at the indicated time points. The data were plotted in a time vs. drug concentration graph.
  • Selected humanized antibodies (SEQ ID NOs: 52 and 82, SEQ ID NOs: 52 and 83, SEQ ID NOs: 109 and 1 15, SEQ ID NOs: 109 and 1 16, SEQ ID NOs: 61 and 9, SEQ ID NOs:4 and 75, SEQ ID NOs: 4 and 78, SEQ ID NOs: 4 and 82, SEQ ID NOs: 4 and 83, SEQ ID NOs: 4 and 98, SEQ ID NOs: 58 and 75, SEQ ID NOs: 58 and 96, SEQ ID NOs: 72 and 108, SEQ ID NOs: 73 and 108, SEQ ID NOs: 4 and 406, and SEQ ID NOs: 405 and 108) described herein display favorable pharmacokinetic profiles or antibody-like pharmacokinetics.
  • Figure 6 The ability of representative humanized PD-1 specific antibodies to release the inhibitory signal through PD-1 via PD-L1 using a PD-1/PD-L1 blockade bioassay as described in Example 10.
  • PD-1-NFAT-luc Jurkat T cells a Jurkat cell line expressing PD- 1 and a NFAT-mediated luciferase gene
  • luciferase assay reagent was added and luminescent signals measured.
  • the humanized PD- 1 specific antibodies inhibitese PD-1/PD-L1 blockade and led to T-cell activation.
  • FIG. 7 shows the results of representative experiments in which the ability of exemplary humanized PD-1 specific antibodies to induce T cell activation was investigated as described in Example 11.
  • human peripheral blood mononuclear cells PBMCs
  • SEB staphylococcal enterotoxin B
  • IL-2 secreted interleukin 2
  • FIG. 8 shows the tumor volume after treatment with selected humanized
  • NOG mice were engrafted with s.c. HCC827 tumors which were allowed to grow for 10 days.
  • Mice were randomized into treatment groups and received 5 c 10 6 fresh human PBMCs intravenously as well as intraperitoneal injections of the humanized PD-1 speicfic antibodies (or control molecules) at the doses indicated on day 1 , day 4, day 8, and day 12. Tumor growth was recorded every 3-4 days.
  • the PD-1 specific antibody of SEQ ID NOs: 109 and 115 successfully inhibited the tumor growth.
  • the present disclosure provideshumanized antibodies that binds PD-1 with high affinity and specificity and that exhibit favorable stability and pharmackenetic profiles as well as useful application and methods of characterizing such antibodies. Additionally, in some embodiments, the disclosed humanized PD-1 specific antibodies are cross-reactive with human and cynomolgus PD-1. No such humanized antibodies having these features attendant to the uses provided by present disclosure have been previously described.
  • Some embodiments of the current disclosure relate to humanized PD-1 specific antibodies obtained by CDR-grafting of a murine antibody specific for human PD-1 , e.g., 388D4 antibody.
  • the technology of CDR-grafting is well-known in the art, where complementarity-determining regions (CDRs) of the antibody light and heavy chain variable regions are grafted into frameworks (FRs) from another species.
  • CDRs complementarity-determining regions
  • FRs frameworks
  • murine CDRs can be grafted into human FRs.
  • the CDRs of the light and heavy chain variable regions of a murine anti-PD-1 antibody are grafted into human FRs or consensus human FRs.
  • CDR-grafting is described in, e.g., U.S. Patent Nos. 7,022,500; 6,982,321 ; 6,180,370; 6,054,297; 5,693,762; 5,859,205; 5,693,761 ; 5,565,332; 5,585,089; and 5,530,101 and PCT International Application Publication Nos.: WO 2016/102716.
  • human light and heavy variable regions in generating humanized antibodies is important to retain the affinity and the specificity of the original murine antibody and reduce antigenicity. As is further discussed herein, such selection can be particularly influential since the antigen specificity often helps eliminate undesired off- target antibody interactions, which in turn affects the pharmacokinetics, tissue distribution, efficacy and toxicity of an antibody. Online databases of mature human IgG sequences can be searched for comparison to the murine light and heavy chain variable regions. In general, the human sequence that is closest to that of the murine is then accepted as the FR for the humanized antibody (Sims et al., J Immunol, 1993, Chothia and Lesk, J Mol Biol, 1987).
  • Another method for making humanized antibodies includes uses of a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains.
  • the same framework may be used for several different humanized antibodies (Presta et al., J Immunol, 1993, Carter et al., Proc Natl Acad Sci U S A, 1992).
  • humanized antibodies can be further analyzed and engineered against parental sequences and using three-dimensional models of the parental and humanized sequences.
  • Three-dimensional immunoglobulin models are commonly available and are known to those skilled in the art.
  • Computer programs that illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences are available. Inspection of these displays permits analyses of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen.
  • FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved.
  • an isolated antibody or antigen-binding fragment thereof has at least one of a heavy chain variable domain comprising complementarity determining regions (CDRs) from the heavy chain variable region sequence set forth in SEQ ID NO: 2, and a light chain variable domain comprising CDRs from the light chain variable region sequence set forth in SEQ ID NO: 3.
  • CDRs complementarity determining regions
  • such an isolated antibody or antigen-binding fragment thereof contains the heavy chain and light chain CDRs of the monoclonal antibody 388D4 but a different framework from the 388D4 antibody.
  • the heavy chain variable region of a provided humanized PD-1 specific antibody or the antigen-binding fragment thereof comprise CDRs with the following sequences: GYTFTDYE (HCDR1 , SEQ ID NO: 28), IDPGTGGT (HCDR2, SEQ ID NO: 29), TSEKFGSNYYFDY (HCDR3, SEQ ID NO: 30).
  • the light chain variable region of a provided humanized PD-1 specific antibody or the antigen-binding domain thereof comprise CDRs with the following sequences: QTIVHSDGNTY (LCDR1 , SEQ ID NO: 31 ), KVS (LCDR2), FQGSHVPLT (LCDR3, SEQ ID NO: 33).
  • CDR1 consists of positions 27 to 38
  • CDR2 consists of positions 56 to 65
  • CDR3 for germline V-genes consists of positions 105 to 1 16
  • CDR3 for rearranged V-J-genes or V-D-J-genes consists of positions 105 to 1 17 (position preceding J-PHE or J-TRP 118) with gaps at the top of the loop for rearranged CDR3-IMGT with less than 13 amino acids, or with additional positions 1 12.1 , 11 1.1 , 112.2, 1 11.2, etc. for rearranged CDR3-IMGT with more than 13 amino acids.
  • the positions given in this paragraph are according to the IMGT numbering described in Lefranc (1999).
  • a provided isolated antibody that binds to PD-1 or the antigen-binding fragment thereof comprises a heavy chain variable domain selected from the group consisting of SEQ ID NOs: 119-159 and 195-199.
  • a provided isolated antibody that binds to PD-1 or the antigen-binding fragment thereof comprises a heavy chain variable domain selected from the group consisting of SEQ ID NOs: 144, 147, 158, 159, and 195.
  • a provided isolated antibody that binds to PD-1 or the antigen-binding fragment thereof comprises a heavy chain variable domain selected from the group consisting of SEQ ID NOs: 144 and 195.
  • a provided isolated antibody that binds to PD-1 or the antigen-binding fragment thereof comprises a light chain variable domain selected from the group consisting of SEQ ID NOs: 160-194, 200-204, and 407.
  • a provided isolated antibody that binds to PD-1 or the antigen-binding fragment thereof comprises a light chain variable domain selected from the group consisting of SEQ ID NOs: 161 , 165, 168, 169, 182, 184, 194, 201 , 202, and 407.
  • a provided isolated antibody that binds to PD-1 or the antigen-binding fragment thereof comprises a light chain variable domain selected from the group consisting of SEQ ID NOs: 168, 169, 201 , and 202.
  • a provided isolated antibody that binds to PD-1 or the antigen-binding fragment thereof comprises a heavy chain variable domain selected from the group consisting of SEQ ID NOs: 119-159 and 195-199 and a light chain variable region selected from the group consisting of SEQ ID NOs: 160-194, 200-204, and 407.
  • a provided isolated antibody that binds to PD-1 or the antigen-binding fragment thereof comprises a heavy chain variable domain selected from the group consisting of SEQ ID NOs: 144, 147, 158, 159, and 195 and a light chain variable region selected from the group consisting of SEQ ID NOs 161 , 165, 168, 169, 182, 184, 194, 201 , 202, and 407.
  • a provided isolated antibody that binds to PD-1 or the antigen-binding fragment thereof comprises a heavy chain variable domain selected from the group consisting of SEQ ID NOs: 144 and 195 and a light chain variable region selected from the group consisting of SEQ ID NOs: 168, 169, 201 , and 202.
  • a provided isolated antibody that binds to PD-1 or the antigen-binding fragment thereof comprises a heavy chain variable domain and light chain variable domain pair having the amino acid sequences selected from the group consisting of SEQ ID NOs:144 and 168, SEQ ID NOs: 144 and 169, SEQ ID NOs: 195 and 201 , SEQ ID NOs: 195 and 202, SEQ ID NOs: 147 and 21 , SEQ ID NOs:16 and 161 , SEQ ID NOs:16 and 165, SEQ ID NOs: 16 and 168, SEQ ID NOs: 16 and 169, SEQ ID NOs: 16 and 184, SEQ ID NOs: 144 and 161 , SEQ ID NOs: 144 and 182, SEQ ID NOs: 158 and 194, SEQ ID NOs: 159 and 194,
  • a provided isolated antibody that binds to PD-1 or the antigen-binding fragment thereof have a heavy chain variable region with at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97.5%, at least 98%, at least 98.5%, or at least 99% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 119-159 and 195-199, and a light chain variable region with at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97.5%, or at least 98% to an amino acid sequence selected from the group consisting of SEQ ID NOs: 160- 194, 200-204, and 407.
  • a provided isolated antibody that binds to PD-1 or the antigen-binding fragment thereof have a heavy chain variable region with at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97.5%, at least 98%, at least 98.5%, or at least 99% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 144, 147, 158, 159, and 195, and a light chain variable region with at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97.5%, or at least 98% to an amino acid sequence selected from the group consisting of SEQ ID NOs: 161 , 165, 168, 169, 182, 184, 194, 201 , 202, and 407.
  • a provided isolated antibody that binds to PD-1 or the antigen-binding fragment thereof have a heavy chain variable region with at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97.5%, at least 98%, at least 98.5%, or at least 99% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 144 and 195, and a light chain variable region with at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97.5%, or at least 98% to an amino acid sequence selected from the group consisting of SEQ ID NOs: 168, 169, 201 , and 202.
  • a provided isolated antibody that binds to PD-1 or the antigen-binding fragment thereof comprises a heavy chain variable domain and light chain variable domain pair having at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97.5%, at least 98%, at least 98.5%, or at least 99% sequence identity to the amino acid sequences selected from the group consisting of SEQ ID NOs:144 and 168, SEQ ID NOs: 144 and 169, SEQ ID NOs: 195 and 201 , SEQ ID NOs: 195 and 202, SEQ ID NOs: 147 and 21 , SEQ ID NOs:16 and 161 , SEQ ID NOs:16 and 165, SEQ ID NOs: 16 and 168, SEQ ID NOs: 16 and 169, SEQ ID NOs: 16 and 184, SEQ ID NOs: 144 and 161 , SEQ ID NOs: 144 and 182, SEQ ID NOs: 158
  • a provided isolated antibody that binds to PD-1 is or comprises a full-length immunoglobulin.
  • the immunoglobulin for example, may be lgG1 , lgG2 or lgG4.
  • a provided antibody is, in some embodiments, a full-length antibody (also called a full-length immunoglobulin) or an antibody that contains a portion of the Fc region.
  • the choice of the Fc region depends on the desired effector functions like complement fixation or antibody- dependent cell-mediated cytotoxicity are desirable features.
  • a provided isolated antibody that binds to PD-1 may comprise an Fc region that allows for extended in vivo half-life.
  • Fc region is preferably from human origin, more preferably a human Fc region of an lgG1 or lgG4 antibody, even more preferably an engineered human Fc region of an lgG1 or lgG4 with activating or silencing effector functions, wherein silencing effector functions are preferred over activating effector functions.
  • PD-1 may comprise an Fc region which allows for reduced or fully suppressed Fc receptor binding. This may be achieved, for example, by using an lgG4 backbone or switching from the lgG1 backbone to lgG4, as lgG4 is known to display reduced Fc-gamma receptor interactions, including as compared to lgG1.
  • mutations may be introduced into the lgG4 backbone, such as F234A and L235A, to further reduce the residual binding to Fc-gamma receptors.
  • an S228P mutation may be introduced into the lgG4 backbone to minimize the exchange of lgG4 half-antibody.
  • M428L and N434S or M252Y, S254T, and T256E may be introduced into the lgG4 backbone for enhanced binding to the neonatal Fc receptor and extended serum half-life.
  • an additional N297A mutation may be present in the immunoglobulin heavy chain of the antibody in order to remove the natural glycosylation motif resulting in decreased binding to Fc-gamma receptor and reduced or eliminated antibody cytotoxicity. Numbering for all sets of these potential mutations is according to EU index of Kabat (Johnson and Wu, Nucleic Acids Res, 2000).
  • PD-1 or the antigen-binding domain thereof comprises a heavy chain having the sequence selected from SEQ ID NOs: 33-73, 109-113, and 405.
  • the isolated antibody that binds to PD-1 or the antigen-binding domain thereof comprises a light chain having the sequence selected from SEQ ID NOs: 74-108, 114-118, and 406.
  • a provided isolated antibody that binds to PD-1 or the antigen-binding domain thereof comprises a heavy chain having the sequence selected from SEQ ID NOs: 58, 61 , 72, 73, 109, and 405. In some further embodiments, the isolated antibody that binds to PD-1 or the antigen-binding domain thereof comprises a light chain having the sequence selected from SEQ ID NOs: 75, 78, 82, 83, 96, 98, 108, 115, 116, and 406. [0076] In some embodiments, a provided isolated antibody that binds to PD-1 or the antigen-binding domain thereof comprises a heavy chain having the sequence selected from SEQ ID NOs: 58 and 109. In some further embodiments, the isolated antibody that binds to PD-1 or the antigen-binding domain thereof comprises a light chain having the sequence selected from SEQ ID NOs: 82, 83, 115, and 116.
  • PD-1 or the antigen-binding fragment thereof comprises a heavy chain and light chain pair having the amino acid sequences selected from the group consisting of SEQ ID NOs: 58 and 82, SEQ ID NOs: 58 and 83, SEQ ID NOs: 109 and 115, SEQ ID NOs: 109 and 116, SEQ ID NOs: 61 and 9, SEQ ID NOs:4 and 75, SEQ ID NOs: 4 and 78, SEQ ID NOs: 4 and 82, SEQ ID NOs: 4 and 83, SEQ ID NOs:4 and 98, SEQ ID NOs: 58 and 75, SEQ ID NOs: 58 and 96, SEQ ID NOs: 72 and 108, SEQ ID NOs: 73 and 108, SEQ ID NOs: 4 and 406, SEQ ID NOs: 405 and 108.
  • a provided PD-1 antibody or antigen-binding domain thereof have a heavy chain with at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97.5%, at least 98%, at least 98.5%, or at least 99% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 33-73, 109-113, and 405 and a light chain with at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97.5, at lest 98%, at least 98.5%, or at least 99% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 74-108, 114-118, and 406.
  • a provided PD-1 antibody or antigen-binding domain thereof have a heavy chain with at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97.5%, at least 98%, at least 98.5%, or at least 99% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 58, 61 , 72, 73, 109, 405, and a light chain with at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97.5, at lest 98%, at least 98.5%, or at least 99% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 75, 78, 82, 83, 96, 98, 108, 1 15, 116, and 406.
  • a provided PD-1 antibody or antigen-binding domain thereof have a heavy chain with at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97.5%, at least 98%, at least 98.5%, or at least 99% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 58 and 109 and a light chain with at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97.5, at lest 98%, at least 98.5%, or at least 99% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 82, 83, 115, and 116.
  • PD-1 or the antigen-binding fragment thereof comprises a heavy chain and light chain pair having at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97.5%, at least 98%, at least 98.5%, or at least 99% sequence identity to the amino acid sequences selected from the group consisting of SEQ ID NOs: 58 and 82, SEQ ID NOs: 58 and 83, SEQ ID NOs: 109 and 115, SEQ ID NOs: 109 and 116, SEQ ID NOs: 61 and 9, SEQ ID NOs:4 and 75, SEQ ID NOs: 4 and 78, SEQ ID NOs: 4 and 82, SEQ ID NOs: 4 and 83, SEQ ID NOs:4 and 98, SEQ ID NOs: 58 and 75, SEQ ID NOs: 58 and 96, SEQ ID NOs: 72 and 108, SEQ ID NOs: 73 and 108, SEQ ID NOs: 4 and 406, SEQ
  • a provided PD-1 antibody or antigen-binding fragment thereof binds to a sequence in PD-1 selected from the group consisting of SEQ ID NOs: 355- 385.
  • a provided isolated PD-1 antibody or an antigen-binding fragment thereof that competitively inhibits the binding of a reference antibody to a target or binds to the same epitope of the target as a reference antibody or an antigen-binding domain thereof is specifically contemplated as within the scope of the present disclosure.
  • a provided antibody competitively inhibits the binding or binds to the same epitope of a target as a reference antibody that comprises an antigen-binding region, such as any one of the three heavy chain CDRs and the three light chain CDRs, from any one of the anti-PD-1 antibodies disclosed in above mentioned applications.
  • the antibody competitively inhibits the binding or binds to the same epitope of the antibody that comprises a heavy chain variable domain and light chain variable domain pair selected from the group consisting of SEQ ID NOs:144 and 168, SEQ ID NOs: 144 and 169, SEQ ID NOs: 195 and 201 , and SEQ ID NOs: 195 and 202.
  • a provided antibody competitively inhibits the binding or binds to the same epitope of the target of a reference antibody that comprises a heavy chain and light chain pair selected from the group consisting of SEQ ID NOs: 58 and 82, SEQ ID NOs: 58 and 83, SEQ ID NOs: 109 and 115, and SEQ ID NOs: 109 and 1 16.
  • some embodiments of the current disclosure relate to an isolated antibody binding to PD-1 or an antigen-binding fragment thereof that binds PD-1 , preferably human PD-1 , with an affinity measured by a K d of about 20 nM, 15 nM, 5 nM, 3 nM, or lower.
  • affinity can be determined, for example, by surface plasmon resonance (SPR) analysis essentially described in Example 3.
  • a provided PD-1 specific antibody or the antigen- binding fragment thereof may be cross-reactive with cynomolgus PD-1 , and in some further embodiments, binds cynomolgus PD-1 with an affinity measured by a K d of about 50 nM, 40 nM, 10 nM, or lower.
  • affinity can be determined, for example, by SPR analysis essentially described in Example 3.
  • a provided humanized PD-1 specific antibody or antigen-binding fragment thereof binds PD-1 with substantially the same or lower K d as an antibody having a heavy chain comprising the amino acid sequence of SEQ ID NO: 4 and a light chain comprising the amino acid sequence of SEQ ID NO: 9 or as an antibody having a heavy chain comprising the amino acid sequence of SEQ ID NO: 16 and a light chain comprising the amino acid sequence of SEQ ID NO: 21.
  • a provided isolated antibody or an antigen-binding fragment thereof binds PD-1 with an EC 50 value of at most about 10 nM or even lower, such as about 5 nM, about 1 nM, about 0.5 nM, about 0.2 nM, about 0.15 nM, about 0.1 nM, or even lower.
  • a provided isolated antibody or an antigen-binding domain thereof binds cynomolgus PD-1 with an EC 50 value of at most about 10 nM or even lower, such as about 5 nM, about 1 nM, about 0.5 nM, about 0.2 nM, about 0.15 nM, about 0.1 nM, or even lower.
  • a provided isolated antibody or an antigen- binding domain thereof binds PD-1 with substantially the same or lower EC 50 value as an antibody having a heavy chain and light chain pair comprising the amino acid sequences of SEQ ID NOs: 4 and 9 or SEQ ID NOs: 16 and 21.
  • the ability of such antibody to bind PD-1 may be determined by, for example, and an enzyme-linked immunosorbent assay (ELISA) essentially described in Example 4.
  • a provided isolated antibody or an antigen-binding fragment thereof binds PD-1 expressed on a cell with an EC 50 value of at most about 10 nM or even lower, such as about 8 nM, about 5 nM, about 2 nM, about 1 nM, or even lower.
  • a provided isolated antibody or an antigen-binding domain thereof binds PD-1 expressed on a cell with substantially the same or lower EC 50 value as an antibody having a heavy chain and light chain pair comprising the amino acid sequences of SEQ ID NOs: 4 and 9 or SEQ ID NOs: 16 and 21 .
  • the ability to bind PD-1 expressed on a cell may be determined by, for example, a fluorescence activated cell sorting (FACS) assay, such as the FACS assay as essentially described in Example 5.
  • FACS fluorescence activated cell sorting
  • the cell expressing PD-1 may, for example, be a CHO cell transfected with human PD-1 or cynomolgus PD-1.
  • a provided isolated antibody or an antigen- binding fragment thereof competes with PD-L1 or PD-L2 for binding to PD-1 .
  • a provided isolated antibody or an antigen-binding domain thereof of the disclosure may be able to compete with PD-L1 or PD-L2 for binding to PD-1 with an IC 50 value of about 10 nM, 6 nM, 5 nM, 4 nM, 3 nM, 1 nM, or even lower.
  • a provided isolated antibody or an antigen-binding domain thereof may be able to compete with PD-L1 or PD-L2 for binding to PD-1 with an IC 50 value that is substantially equal to or lower than the IC 50 value of the antibody having a heavy chain and light chain pair comprising the amino acid sequences of SEQ ID NOs: 4 and 9 or SEQ ID NOs: 16 and 21 .
  • the ability to compete with PD-L1 or PD-L2 may be determined by, for example, an enzyme-linked immunosorbent assay (ELISA) essentially described in Example 6.
  • a provided isolated antibody or an antigen-binding fragment thereof does not essentially bind targets other than PD-1 . Accordingly, a provided isolated antibody or an antigen-binding domain thereof has reduced to targets other than the designated target PD-1 (also called off-target binding) compared to an antibody having a heavy chain and light chain pair comprising the amino acid sequences of SEQ ID NOs: 16 and 21 or SEQ ID NOs: 4 and 9.
  • targets other than the designated target PD-1 also called off-target binding
  • Such evaluation of off target binding can be performed by ELISA as described in Example 7.
  • a provided isolated antibody or an antigen- binding domain thereof does not essentially bind cells that do not express PD-1 . Accordingly, a provided isolated antibody or an antigen-binding domain thereof has reduced nonspecific binding to cells that do not express PD-1 compared to an antibody having a heavy chain and light chain pair comprising the amino acid sequences of SEQ ID NOs: 16 and 21 or SEQ ID NOs: 4 and 9. Such evaluation of non-specific binding can be performed by fluorescence- activated cell sorting (FACS) as described in Example 8.
  • FACS fluorescence- activated cell sorting
  • a provided PD-1 antibody or antigen-binding domain thereof have favorable stability and pharmacokinetics profiles.
  • a provided PD-1 antibody or antigen-binding domain thereof have comparable pharmacokinetics profile compared to an antibody having a heavy chain and light chain pair comprising the amino acid sequences of SEQ ID NOs: 16 and 21 or SEQ ID NOs: 4 and 9.
  • a provided PD-1 antibody or antigen-binding domain thereof have antibody-like pharmacokinetics. As described herein, a favorable pharmacokinetic profile or an antibody-like pharmacokinetics may be considered to be achieved for provided antibodies if the percentage of c max was above 15 % after 168 h. Pharmacokinetics profiles of provided antivodies may be analyzed as described in Example 9.
  • a provided PD-1 antibody or antigen-binding domain thereof blocks the inhibitory signal of PD-1. In some embodiments, a provided PD-1 antibody or antigen-binding domain thereof releases a brake for T cell activation or leads to successful T cell activation.
  • the blockade of PD-1 inhibitory signal or T cell activation may be measured, for example, in a PD-1/PD-L1 blockade bioassay as described in Example 10.
  • a provided PD-1 antibody or antigen-binding domain thereof can enhance IL-2 secretion.
  • a provided PD-1 antibody or antigen-binding domain thereof may demonstrate a tendency to induce more enhanced IL-2 secretion at higher concentrations.
  • a provided PD-1 antibody or antigen-binding domain thereof induces dose-dependent increase of IL-2 secretion, comparable to an antibody having a heavy chain and light chain pair comprising the amino acid sequences of SEQ ID NOs: 4 and 9.
  • a provided PD-1 antibody or antigen-binding domain thereof can lead to successful T cell activation.
  • the IL-2 secretion or T cell activation may be measured, for example, in in a functional T-cell activation assay as described in Example 11.
  • a provided PD-1 antibody or antigen-binding domain thereof can inhibit tumor growth.
  • the tumor growth inhibition may be demonstrated in humanized mouse tumor model as described in Example 12.
  • the present disclosure additionally encompasses nucleic acid molecules and host cells encoding a probided anti-PD-1 antibodies or antigen-binding domains thereof as described herein.
  • An anti-PD-1 antibody of the present disclosure can be prepared by recombinant expression of immunoglobulin heavy and light chain genes.
  • nucleotide sequence encoding the heavy and light chain variable regions are first obtained.
  • the presentdisclosure also provides isolated nucleic acids comprising a nucleotide sequence encoding a heavy or light chain variable region as disclosed herein, or a fragment thereof.
  • nucleic acid fragments encoding the heavy and light chain variable regions are obtained, resultant fragments can be further manipulated or ligated to other appropriate necleotide sequences by standard recombinant techniques, for example, to convert the variable region genes to full-length antibody chain genes, to Fab fragment genes, or to a scFv gene.
  • a nucleic acid fragments encoding the heavy and light chain variable region is operatively linked to another fragment encoding another protein, such as an antibody constant region or a flexible linker.
  • the term "operatively linked” as used herein refers to that the two nucleic acid fragments are joined such that the amino acid sequences encoded by the two remain in-frame.
  • a nucleic acid according to the present invention may comprise DNA or RNA, and may be wholly or partially synthetic. Production of defined gene constructs is within routine skill in the art. See, e.g., Current Protocols in Molecular Biology, Second Edition, Ausubel et al. eds., John Wiley & Sons, 1992.
  • nucleotide sequences of a provided anti-PD-1 antibody or the fragment thereof can be cloned out of hybridomas, for example, by conventional hybridization techniques or polymerase chain reaction (PCR) techniques, using synthetic nucleic acid probes or primers whose sequences are based on sequence information provided herein, or known sequence information regarding genes encoding the heavy and light chains of murine antibodies in hybridoma cells.
  • PCR polymerase chain reaction
  • a provided nucleotide sequence(s) encoding an anti- PD-1 antibody or the fragment thereof can be operably linked to a promoter to effect expression of the antibody in a host cell.
  • the sequence may include at its 5' end a leader sequence to facilitate expression in a host cell and/or secretion of the antibody from a host cell. Suitable leader sequences are known in the art and can be selected by the skilled person, taking account of the host cell.
  • the nucleic acid is incorporated into a vector.
  • Suitable vectors containing appropriate regulatory sequences can be obtained commercially or constructed by persons of skill in the art. For further details see, e.g., Molecular cloning: a laboratory manual, 3rd edition, Sambrook et al., 2001. Examples of vectors include plasmids, phages, phagemids, and cosmids, as well as transcription and expression cassettes.
  • a provided nucleotide sequence encoding an anti-PD- 1 antiobdy or a fragment thereof is incorporated into an expression vector, which is introduced into host cells through conventional transfection or transformation techniques. Accordingly, a host cell can be transformed with an expression vector comprising a nucleotide sequence encoding an anti-PD-1 antiobdy or a fragment thereof.
  • host cells include E. coli cells, Chinese hamster ovary (CHO) cells, human embryonic kidney 293 (HEK 293) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), and human hepatocellular carcinoma cells.
  • a provided method comprises: (a) growing a host cell containing an expression vector encoding the anti-PD-1 antiobdy or a fragment thereof under conditions so that the host cell expresses the antibody or a fragment thereof; and (b) isolating the antibody or a fragment thereof.
  • Suitable conditions for antibody expression and isolation or purification depend on the expression system employed. For example, if a gene is to be expressed in E. coli, it is first cloned into an expression vector by positioning the engineered gene downstream from a suitable bacterial promoter, e.g., Tip or Tac, and a prokaryotic signal sequence. The expressed secreted protein accumulates in refractile or inclusion bodies, and can be harvested after disruption of the cells by French press or sonication. The refractile bodies then are solubilized, and the proteins refolded and cleaved by methods known in the art.
  • a suitable bacterial promoter e.g., Tip or Tac
  • an engineered gene is to be expressed in eukaryotic host cells, e.g., CHO (Chinese hamster ovary) cells, it is first inserted into an expression vector containing a suitable eukaryotic promoter, a secretion signal, a poly A sequence, and a stop codon.
  • a provided vector or gene construct contains enhancers and introns.
  • a provided expression vector optionally contains sequences encoding all or part of a constant region, enabling an entire, or a part of, a heavy or light chain to be expressed.
  • a provided gene construct can be introduced into eukaryotic host cells using conventional techniques.
  • Provided host cells may express VL or VH fragments, VL-VH heterodimers, VH-VL or VL-VH single chain polypeptides, complete heavy or light immunoglobulin chains, portions thereof, and any combination thereof each of which may be attached to a moiety having another function ⁇ e.g., cytotoxicity).
  • a host cell may be transfected with a vector containing the entire or part of a heavy chain or a light chain (e.g., a heavy or light chain variable region).
  • a host cell may be transfected with a vector encoding (a) a polypeptide comprising a heavy chain variable region and a polypeptide comprising a light chain variable region, or (b) an entire immunoglobulin heavy chain and an entire immunoglobulin light chain.
  • a host cell may be co-transfected with more than one expression vector (e.g., one expression vector expressing a polypeptide comprising an entire or part of a heavy chain or heavy chain variable region, and another expression vector expressing a polypeptide comprising an entire or part of a light chain or light chain variable region).
  • more than one expression vector e.g., one expression vector expressing a polypeptide comprising an entire or part of a heavy chain or heavy chain variable region, and another expression vector expressing a polypeptide comprising an entire or part of a light chain or light chain variable region.
  • a polypeptide comprising an immunoglobulin heavy chain variable region or light chain variable region can be produced, for example, by growing (culturing) a host cell transfected with an expression vector encoding such a variable region, under conditions that permit expression of the polypeptide. Following expression, the polypeptide can be harvested and purified or isolated using techniques known in the art, e.g., affinity tags such as Protein A, Protein G, glutathione-S-transferase (GST), or histidine tags.
  • affinity tags such as Protein A, Protein G, glutathione-S-transferase (GST), or histidine tags.
  • Anti-PD-1 antibodies as described herein can be produced by growing (culturing) a host cell transfected with, for example: (a) an expression vector that encodes a complete or partial immunoglobulin heavy chain, and a separate expression vector that encodes a complete or partial immunoglobulin light chain; or (b) a single expression vector that encodes both chains (e.g., complete or partial heavy and light chains), under conditions that permit expression of both chains.
  • the intact antibody (or antigen-binding fragment) can be harvested and purified or isolated using techniques known in the art, e.g., Protein A, Protein G, affinity tags such as glutathione-S-transferase (GST) or histidine tags. It is within ordinary skill in the art to express a heavy chain and a light chain from a single expression vector or from two separate expression vectors.
  • an anti-PD-1 antibody or a fragment thereof of the disclosure may belinked to one or moreadditional functional molecules or moieties, e.g., a peptide, protein, toxin, radioisotope, or cytostatic agent, for various purposes such as in vivo diagnostic imaging or a diagnostic assay.
  • additional functional molecules or moieties e.g., a peptide, protein, toxin, radioisotope, or cytostatic agent
  • Provided antibodies can be linked by one or more chemical cross-linking or by recombinant methods.
  • provided antibodies also can be linked to any of various nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos.
  • Antibodies can be chemically modified by covalent conjugation to a polymer, for example, to increase their circulating half-life. Examples of polymers and methods to attach them are described in U.S. Patent Nos. 4,766,106; 4,179,337; 4,495,285; and 4,609,546.
  • provided anti-PD-1 antibodies of the present disclosure are formulated into pharmaceutical compositions suitable for administration to a mammal, e.g., a human patient.
  • Provided compositions typically comprise one or more antibodies described herein and a pharmaceutically acceptable excipient.
  • pharmaceutically acceptable excipient includes suitable solvents, dispersion media, coatings, antibacterial agents and antifungal agents, isotonic agents, and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is known in the art.
  • Provided compositions also can contain one or more other active compounds providing supplemental, additional, or enhanced therapeutic functions.
  • the pharmaceutical compositions also can be included in a container, pack, or dispenser together with instructions for administration.
  • compositions may be formulated to be compatible with an intended route of administration.
  • Methods to accomplish the administration are known in the art.
  • the administration may be, for example, intravenous, intraperitoneal, intramuscular, intracavity, subcutaneous, intradermal, topical, inhalation, transmucosal, rectal or transdermal.
  • Solutions or suspensions used for intradermal or subcutaneous application typically include one or more of the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol, or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfate; chelating agents such as EDTA; buffers such as acetates, citrates or phosphates; and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • the pH can be adjusted with acids or bases, as necessary.
  • Such preparations may be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • compositions suitable for injection include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. Sterilization can be accomplished, for example, by filtration through sterile filtration membranes.
  • suitable carriers include, for example, physiological saline, bacteriostatic water, Cremophor EL (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
  • a pharmaceutical composition is stable under the conditions of manufacture and storage and is preserved against contamination by microorganisms such as bacteria and fungi.
  • Avoidance of microorganisms can be achieved by inclusion of antibacterial and/or antifungal agents.
  • examples include: parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, and sodium chloride in the composition.
  • a carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol such as glycerol, propylene glycol, liquid polyethylene glycol, and the like, and suitable mixtures thereof.
  • proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and/or by the use of surfactants.
  • Prolonged absorption of injectable compositions can be achieved by including in the composition an agent that delays absorption, e.g., aluminum monostearate or gelatin.
  • oral compositions generally include an inert diluent or an edible carrier.
  • provided oral compositions can be enclosed in gelatin capsules or compressed into tablets.
  • provided antibodies can be combined with excipients and used in the form of tablets, troches, or capsules.
  • one or more penetrants appropriate to the barrier to be permeated can be used in the formulation.
  • penetrants are known in the art, and include, for example, detergents, bile salts, and fusidic acid derivatives.
  • Transmucosal administration may be accomplished, for example, through the use of lozenges, nasal sprays, inhalers, or suppositories.
  • compositions may be capable of transmission across mucous membranes in intestine, mouth, or lungs (e.g., via the FcRn receptor-mediated pathway as described in U.S. Pat. No. 6,030,613).
  • provided antibodies may be formulated into ointments, salves, gels, or creams as generally known in the art.
  • provided antibodies may be delivered in the form of an aerosol spray from pressured container or dispenser, which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
  • provided antibodies and/or antigen-binding domains thereof are formulated with carriers that protect the antibody against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used. Exemplary polymers include ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
  • Liposomal suspensions containing the presently disclosed antibodies can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known in the art. See, e.g., U.S. Patent No. 4,522,811.
  • compositions contain, in addition to a provided antibody, at least one of a cytotoxic agent, cytostatic agent, anti-angiogenic agent, a tumor targeted agent, an immune stimulating agent or immune modulating agent, or an antibody conjugated to a cytotoxic, cytostatic, or otherwise toxic agent.
  • a cytotoxic agent cytostatic agent
  • anti-angiogenic agent a tumor targeted agent
  • an immune stimulating agent or immune modulating agent or an antibody conjugated to a cytotoxic, cytostatic, or otherwise toxic agent.
  • the pharmaceutical composition optionally can be employed with other therapeutic modalities such as surgery, chemotherapy, and radiation.
  • Toxicity and therapeutic efficacy of certein embodiments can be determined by conventional pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population).
  • the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD 5 o/ED 50 .
  • Compositions that exhibit large therapeutic indices are preferred.
  • a therapeutically effective dose of a provided antibody can be estimated initially, e.g., from cell culture assays.
  • suitable bioassays include but are not limited to, DNA replication assays, cytokine release assays, transcription-based assays, PD- 1/PD-L1 binding assays, creatine kinase assays, assays based on the differentiation of pre- adipocytes, assays based on glucose uptake in adipocytes, immunological assays other assays as, for example, described in the Examples.
  • the data obtained from the cell culture assays and animal studies can be used in formulating a range of dosing regimen for use in humans.
  • a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC 50 (i.e., the concentration of the antibody that achieves a half-maximal inhibition of symptoms). Circulating levels in plasma may be measured, for example, by high performance liquid chromatography. The effects of any particular dosage can be monitored by a suitable bioassay. The dosage lies preferably within a range of circulating concentrations with little or no toxicity. The dosage may vary depending upon the dosage form employed and the route of administration.
  • a therapeutically effective amount of an antibody or a composition described herein is in the range of 0.1 mg/kg to 100 mg/kg, preferably 0.1 mg/kg to 50 mg/kg.
  • the amount administered will depend on variables such as the type and extent of disease or indication to be treated, the overall health of the patient, the in vivo potency of the antibody, the pharmaceutical formulation, the serum half-life of the antibody, and the route of administration.
  • Administration frequency can vary, depending on factors such as route of administration, dosage amount, serum half-life of the antibody or fusion protein, and the disease being treated.
  • PD-1 is a cell surface signaling receptor that plays a critical role in the regulation of T cell activation and tolerance (Keir et al., Annu Rev Immunol, 2008). It is a type I transmembrane protein and together with BTLA, CTLA-4, ICOS, and CD28, comprise the CD28 family of T cell co-stimulatory receptors. PD-1 is primarily expressed on activated T cells, B cells, and myeloid cells (Dong et al., Nat Med, 1999). It is also expressed on natural killer (NK) cells (Terme et al., Cancer Res, 2011 ).
  • NK natural killer
  • PD-1 One important role of PD-1 is to limit the activity of T cells in peripheral tissues at the time of an inflammatory response to infection, thus limiting the development of autoimmunity (Pardoll, Nat Rev Cancer, 2012).
  • humanized antibodies of the disclosure may generate a durable anti-tumor and/or anti-infection response, increase anti- tumor lymphocyte cell activity, and/or enhance anti-tumor immunity. Numerous possible applications for humanized anti-PD1 antibodies of the disclosure, therefore, exist in medicine.
  • the present disclosure relates to the use of the humanized anti-PD1 antibodies disclosed herein for detecting or binding PD-1 in a sample as well as a corresponding method of diagnosis.
  • Such use may include the steps of contacting one or more provided humanized anti-PD1 antibodies, under suitable conditions, with a sample suspected of containing PD-1 , thereby allowing the formation of a complex between the humanized anti-PD1 antibodies and PD-1 , and detecting the complex by a suitable signal.
  • the detectable signal can be caused by a label, as explained above, or by a change of physical properties due to the binding, i.e., the complex formation, itself.
  • One example is surface plasmon resonance, the value of which is changed during binding of binding partners from which one is immobilized on a surface such as a gold foil.
  • the present disclosure provdies a diagnostic or analytical kit comprising a humanized anti-PD1 antibody according to the disclosure.
  • humanized anti-PD1 antibodies disclosed herein are used in diagnosing a PD-1 -mediated adaptive immune resistance in a patient who has cancer.
  • Such use comprises contacting a tumor microenvironment in the patient with an antibody disclosed herein that has been labeled with a detectable moiety and detecting expression of PD-1 on immune cells, e.g., CD 8+ T cells, B cells, and macrophages, within the tumor microenvironment.
  • immune cells e.g., CD 8+ T cells, B cells, and macrophages
  • Such use may further comprise an agent for detecting expression of PD-L1 on immune cells within the tumor microenvironment.
  • Adaptive immune resistance includes suppression of a host immune response as a result of activation of a PD-1 signaling pathway in immune cells of the host.
  • cancer tissue suppresses a host immune response by upregulation of PD-L1 and its binding to PD-1 on immune cells on T cells (such as CD 8+ T cells), B cells, and macrophages.
  • diagnostic uses of provided anti-PD-1 antibodies can be performed in vivo, or on a biopsy sample from a patient, wherein the tumor microenvironment is present in a tumor biopsy.
  • antibodies may be modified with a ligand group such as biotin, or a detectable marker group such as a fluorescent group, a radioisotope, or an enzyme.
  • Antibodies of the invention can be labeled using conventional techniques. Suitable detectable labels include: fluorophores, chromophores, radioactive atoms, electron-dense reagents, enzymes, and ligands having specific binding partners. Enzymes typically are detected by their reaction products. For example, horseradish peroxidase can be detected through conversion of tetramethylbenzidine (TMB) to a blue pigment, quantifiable with a spectrophotometer.
  • TMB tetramethylbenzidine
  • suitable binding partners include biotin and avidin or streptavidin, IgG and protein A, and the numerous receptor-ligand couples known in the art. Other permutations and possibilities will be readily apparent to those of ordinary skill in the art.
  • the disclosure contemplates pharmaceutical composition comprising one or more provided humanized anti- PD1 antibodies and a pharmaceutically acceptable excipient.
  • a provided pharmaceutical composition comprising one or more humanized anti-PD1 antibodies of the disclosure has satisfactory or improved safety profile.
  • the satisfactory or improved safety profile results from the the high specificity or reduced or diminished off-target binding of provided anti-PD1 antibodies of the disclosure.
  • the present disclosure encompasses the recognition that a provided anti-PD-1 antibody or a fragment thereof may be used in methods for reactivating an exhausted T cell, comprising contacting a population of T cells with such an antibody or a fragment thereof in vitro, ex vivo, or in vivo.
  • humanized antibodies or fragments thereof that bind PD-1 for use as anti-infection and/or anti-cancer agents and immune modulators.
  • humanized antibodies of the present disclosure are envisaged to be used in a method of treatment or prevention of human diseases, such as a variety of tumors and autoinflammation in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of one or more humanized anti-PD1 antibodies of the disclosure.
  • cancers that may be treated using provided antibodies or fragments of the disclosure, include liver cancer, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, breast cancer, lung cancer, cutaneous or intraocular malignant melanoma, renal cancer, uterine cancer, ovarian cancer, colorectal cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular 20 cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, solid tumors of 25 childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the
  • a human patient suffers from non-small cell lung cancer (NSCLC) or virally-related cancer (e.g., a human papillomavirus (HPV)-related tumor) or gastric adenocarcinoma.
  • NSCLC non-small cell lung cancer
  • HPV human papillomavirus
  • gastric adenocarcinoma is associated with Epstein-Barr virus (EBV) infection.
  • WSCLC non-small cell lung cancer
  • HPV human papillomavirus
  • gastric adenocarcinoma is associated with Epstein-Barr virus (EBV) infection.
  • “treat”, “treating” or “treatment” means inhibiting or relieving a disease or disorder.
  • treatment can include a postponement of development of the symptoms associated with a disease or disorder, and/or a reduction in the severity of such symptoms that will, or are expected, to develop with said disease.
  • the terms include ameliorating existing symptoms, preventing additional symptoms, and ameliorating or preventing the underlying causes of such symptoms.
  • the terms denote that a beneficial result is being conferred on at least some of the subjects, e.g., human patients, being treated. Many medical treatments are effective for some, but not all, patients that undergo the treatment.
  • anti-PD-1 antibodies of the disclosure when used to treat human diseases, can be used alone or in combination with one or more other therapeutic agent.
  • a provided antibody can be linked to, e.g., conjugated to or fused to, an agent (as a complex or fusion protein) or in combination with an agent.
  • therapeutic agents include other checkpoint inhibitors, immunogenic agents, attenuated cancerous cells, tumor antigens (e.g., recombinant proteins, peptides, and carbohydrate molecules), antigen presenting cells such as dendritic cells pulsed with tumor-derived antigen or nucleic acids, immune stimulating cytokines (e.g., JL-2, IFNa2, GM-CSF), and cells transfected with a gene encoding an immune stimulating cytokine (e.g., GM-CSF); chemotherapy, radiotherapy, surgery and any combination thereof.
  • tumor antigens e.g., recombinant proteins, peptides, and carbohydrate molecules
  • antigen presenting cells such as dendritic cells pulsed with tumor-derived antigen or nucleic acids
  • immune stimulating cytokines e.g., JL-2, IFNa2, GM-CSF
  • cells transfected with a gene encoding an immune stimulating cytokine e.g., GM
  • one or more anti-PD-1 antibodies of the disclosure are administered in combination with one or more additional checkpoint inhibitors.
  • an additional checkpoint inhibitor can be targeted against PD-1 or against a different checkpoint molecule, e.g., TIM3, CEACAMI, TIGIT, LAG-3, VISTA, and 0X40.
  • an additionalcheckpoint inhibitor can be a small molecule or a monoclonal antibody.
  • one or more anti-PD-1 antibodies of the disclosure are administered with one or more additional therapeutic agents, e.g., a cytotoxic agent, a radiotoxic agent, or an immunosuppressive agent.
  • a provided antibody can be linked to, e.g., conjugated to or fused to, the agent (as a complex or fusion protein) or administered separately.
  • an additional therapeutic agent is or comprises an immunomodulatory agent or an anti-cancer agent (e.g., a chemotherapeutic agent).
  • an antibody can be administered before, after or concurrently with the agent or can be co-administered with other known therapies.
  • an antibody disclosed herein is used as a targeting agent for delivery of a payload, e.g., a toxin, to a cell expressing PD-1.
  • a payload e.g., a toxin
  • such use may include administering a provided anti-PD-1 antibody conjugated to a payload moiety. Suitable conjugation methods are known in the art.
  • an anti-PD-1 antibody or antigen-binding fragment thereof of the disclosure may be fused or conjugated to a moiety that may confer new characteristics to the antibody, such as enzymatic activity or binding affinity for other targets.
  • suitable moiety include radionuclides, toxins, organic molecules, nucleic acids, therapeutic peptides, antibodies or antibody fragments, and lipocalin muteins (Anticalin®).
  • the resulting fusion proteins or conjugates can be produced by methods well known in the art.
  • an anti-PD-1 antibody or antigen-binding fragment thereof of the disclosure may be included in a bi-, tri-, or multi-specific antibody or an antibody-drug conjugate. Accordingly, the present disclosure encompasses bi-, tri-, or multi- specific antibodies and antibody-drug conjugates comprising a provided anti-PD-1 antibody or antigen-binding fragment thereof.
  • Example 1 Exemplary humanized anti-PD-1 antibodies and Fc- engineered humanized anti-PD-1 antibodies
  • Frameworks were derived from different human germlines including IGHV1- 3 * 01 (SEQ ID NO: 392), IGHV7-4-1 * 02 (SEQ ID NO: 393), IGHV4-4 * 01 (SEQ ID NO: 394), IGHV5-10-1 * 01 (SEQ ID NO: 395), and IGHV3-1 1 * 03 (SEQ ID NO: 396), with some key murine residues substituted back in order to maintain the structure.
  • Frameworks were derived from different human germlines including IGKV2-29 * 02 (SEQ ID NO: 397), IGKV2-30 * 02 (SEQ ID NO: 398), IGKV4-1 * 01 (SEQ ID NO: 399), IGKV3-1 1 * 01 (SEQ ID NO: 400), IGKV1 -6 * 01 (SEQ ID NO: 401 ), and IGKV3-20 * 01 (SEQ ID NO: 402), with some key murine residues substituted back in to maintain the structure.
  • All antibodies described here had an engineered lgG4 backbone, which contained a S228P mutation to minimize lgG4 half-antibody exchange in-vitro and in-vivo (Silva et al., J Biol Chem, 2015).
  • One or more additional mutations in the lgG4 backbones may exist in all antibodies described here, including F234A and L235A mutations for decreased ADCC and ADCP (Glaesner et al., Diabetes Metab Res Rev, 2010) and/or M428L and N434S mutations or M252Y, S254T, and T256E mutations for extended serum half-life (Dall'Acqua et al., J Biol Chem, 2006, Zalevsky et al., Nat Biotechnol, 2010).
  • Example 2 Expression and analysis of humanized anti-PD-1 antibodies
  • Antibodies were purified using Protein A chromatography followed by size- exclusion chromatography (SEC) in phosphate-buffered saline (PBS). After SEC purification, the fractions containing monomeric protein are pooled and analyzed again using analytical SEC.
  • SEC size- exclusion chromatography
  • Example 3 Affinity of humanized antibodies binding to human and cynomolgus PD-1 determined by surface plasmon resonance (SPR)
  • the anti-human IgG Fc antibody (GE Healthcare) was immobilized on a CM5 sensor chip using standard amine chemistry: the carboxyl groups on the chip were activated using 1 -ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDO) and N-hydroxysuccinimide (NHS). Subsequently, anti-human IgG Fc antibody solution (GE Healthcare) at a concentration of 25 pg/mL in 10 mM sodium acetate (pH 5) was applied at a flow rate of 5 pL/min until an immobilization level of 9000-14000 resonance units (RU) was achieved.
  • EEO 1 -ethyl-3-(3-dimethylaminopropyl)-carbodiimide
  • NHS N-hydroxysuccinimide
  • Example 4 Binding of humanized antibodies toward human and cynomolgus PD-1 in enzyme-linked immunosorbent assay (ELISA)
  • ELISA enzyme-linked immunosorbent assay
  • PD-1 specific antibodies After washing with 100 pl_ PBS-0.05%T five times, PD-1 specific antibodies at different concentrations were added to the wells and incubated for 1 h at room temperature, followed by another wash step. Bound antibodies under study were detected by incubation with 1 :5000 diluted anti-human IgG Fc-HRP (Jackson Laboratory) in PBS-0.1 %T-2%BSA. After an additional wash step, fluorogenic HRP substrate (QuantaBlu, Pierce) was added to each well and the fluorescence intensity was detected using a fluorescence microplate reader.
  • fluorogenic HRP substrate QuantaBlu, Pierce
  • Example 5 Binding of humanized antibodies toward human and cynomolgus PD-1 analyzed by flow cytometry
  • CHO cells Chinese hamster ovary (CHO) cells were stably transfected with human PD-1 , cynomolgus PD-1 , or a mock control using the Flp-ln system (Invitrogen) according to the manufacturer ' s instructions.
  • Transfected CHO cells were maintained in Ham ' s F12 medium (Invitrogen) supplemented with 10% Fetal Calf Serum (FCS, Biochrom) and 500 pg/ml Hygromycin B (Roth). Cells were cultured in cell culture flasks according to manufacturer’s instruction (37°C, 5% C02 atmosphere).
  • Binding affinities (EC 50 s) to PD-1 expressing cells of provided humanized 388D4 antibodies of the present disclosure are in the single digit nanomolar range, comparable to the certain previously known humanized antibody SEQ ID NOs: 4 and 9 (summarized in Table 4).
  • Example 6 ELISA analysis of competitive binding of humanized anti-PD- 1 antibodies with PD-L1 and PD-L2
  • An ELISA-based competitive assay was employed to analyze the inhibition of the interaction of PD-1 with PD-L1 and PD-L2 by the humanized 388D4 antibodies.
  • Recombinant human PD-L1-Fc (R&D) or recombinant human PD-L2-Fc (R&D) at a concentration of 1 pg/mL in PBS was coated overnight on microtiter plates at 4°C. After washing with PBS-0.05%T (PBS supplemented with 0.05% (v/v) Tween 20), the plates were blocked with 2% BSA (w/v) in PBS-0.1 %T (PBS supplemented with 0.1% (v/v) Tween 20) for 1 h at room temperature.
  • calibration curves for the quantification of free PD-1 were prepared by applying different concentrations of biotinylated human PD-1-Fc alone to the same assays. The concentration of free (non-neutralized) PD-1 after incubation with PD-1 specific antibodies was calculated from these calibration curves.
  • Example 7 Off-target binding of humanized antibodies analyzed by ELISA
  • An ELISA-based assay was employed to assess the off-target binding of humanized antibodies toward 32 different targets including PD-1 , cell surface receptor, and cytokine.
  • Targets at the concentration of 5 pg/mL in PBS were coated overnight on microtiter plates at 4°C. After washing with PBS-0.05%T (PBS supplemented with 0.05% (v/v) Tween 20), the plates were blocked with 2% BSA (w/v) in PBS-0.1%T (PBS supplemented with 0.1 % (v/v) Tween 20) for 1 h at room temperature.
  • the fluorescence intensity was detected using a fluorescence microplate reader and normalized to the signal of a previously know humanized 388D4 anti-PD-1 antibody (SEQ ID NOs: 4 and 9).
  • the normalized signals of each testing antibody binding to the 32 targets were summed up to yield the cumulated binding ratio for the antibody at a given concentration, i.e., 100 nM or 10 nM.
  • the cumulated binding ratios at 100 nM and 10 nM for each testing antibody were further summed to yield the sum of cumulated binding ratios.
  • the previously know humanized 388D4 anti-PD-1 antibody (SEQ ID NOs: 4 and 9), to which the fluorescence intensity resulting from binding to each of the 32 targets was normalized, has a cumulated binding ratio of 32 when tested at either 100 nM or 10 nM and a sum of cumulated binding ratios of 64.
  • the results are shown in Table 6. Higher the cumulated binding ratio correlates to stronger off-target binding.
  • Certain previously known humanized 388D4 (SEQ ID NOs: 4 and 9) bind strongly to additional targets including cell surface receptor, cytokine, and cytokine mediator. Such undesired off-target binding has been significantly reduced or eliminated in the humanized 388D4 provided herein (SEQ ID NOs: 58 and 82, SEQ ID NOs: 58 and 83, SEQ ID NOs: 109 and 1 15, and SEQ ID NOs: 109 and 116).
  • Example 8 Off-target binding of PD-1 specific antibodies analyzed by fluorescence-activated cell sorting (FACS)
  • FACS Fluorescence-activated cell sorting
  • HUVEC at a confluency of 80% were detached using a trypsin solution (Promocell) following the vendor guidelines and counted.
  • 2.5 x10 4 HUVEC per well were added to each well of a 384 well plate for FACS (V bottom). Cells were then washed twice with PBS and live-death marker (Invitrogen) was added in a 1/500 dilution to each well. The cells were then incubated with humanized 388D4 antibodies or a human lgG4 control antibody (all at 1000 nM or 100 nM) at 4°C for 30 minutes followed by two washing steps using PBS.
  • mice Male CD-1 mice approximately 5 weeks of age (2 mice per timepoint; Charles River Laboratories, Research Models and Services, Germany GmbH) were injected into a tail vein with a PD-1 specific antibody at a dose of 2 mg/kg. Plasma samples from the mice were obtained at the timepoints of 5 min, 24 h, 168 h, and 336 h. Sufficient whole blood - taken under isoflurane anaesthesia - was collected to obtain at least 30-50 mI_ Li-Heparin plasma per animal and time.
  • Plasma drug levels were then analyzed with ELISA.
  • Human PD-1-His was dissolved in PBS (1 pg/mL) and coated overnight on microtiter plates at 4°C. The plate was washed after each incubation step with 80 pL PBS supplemented with 0.05% (v/v) Tween 20 five times. The plates were blocked with PBS/BSA/Tween (PBS containing 2% BSA (w/v) and 0.1 % (v/v) Tween 20) for 1 h at room temperature and subsequently washed. Plasma samples were diluted in PBS/BSA/Tween to 20% plasma concentration, added to the wells, and incubated for 1 h at room temperature. Another wash step followed.
  • Bound agents under study were detected after 1 h incubation with SULFO-TAG Anti-Human Antibody (Mesoscale Discovery) at 1 pg/mL diluted in PBS containing 2% BSA (w/v) and 0.1 % (v/v) Tween 20. After an additional wash step, 25 pL reading buffer was added to each well and the electrochemiluminescence (ECL) signal of every well was read using a Mesoscale Discovery reader. Data were transferred to Excel for analysis and quantification. A calibration curve with standard protein dilutions was prepared.
  • Figure 5 shows plots of the plasma concentration over time for exemplary previously known humanized 388D4 (SEQ ID NOs: 4 and 9 and SEQ ID NOs: 6 and 7), selected presently provided humanized 388D4.
  • Selected humanized 388D4 SEQ ID NOs: 58 and 82, SEQ ID NOs: 58 and 83, SEQ ID NOs: 109 and 1 15, SEQ ID NOs: 109 and 1 16, SEQ ID NOs: 61 and 9, SEQ ID NOs:4 and 75, SEQ ID NOs: 4 and 78, SEQ ID NOs: 4 and 82, SEQ ID NOs: 4 and 83, SEQ ID NOs: 4 and 98, SEQ ID NOs: 58 and 75, SEQ ID NOs: 58 and 96, SEQ ID NOs: 72 and 108, SEQ ID NOs: 73 and 108, SEQ ID NOs: 4 and 406, and SEQ ID NOs: 405 and 108) described herein display comparable pharmacokinetic profiles as
  • Example 10 Assessment of T cell activation using a PD-1/PD-L1 blockade bioassay
  • PD-1-NFAT-luc Jurkat T cells a Jurkat cell line expressing PD-1 with a luc gene (firefly luciferase gene) driven by a NFAT- responsive element
  • Raji cells over-expressing PD-L1.
  • PD-1/PD-L1 interaction between both cell types inhibits TCR signaling and NFAT-mediated luciferase activity in PD-1-NFAT-luc Jurkat T cells.
  • Addition of a PD-1/PD-L1 blocking agent, such as humanized 388D4 results in releasing PD-1/PD-L1 block on NFAT-mediated luminescence.
  • Raji cells over-expressing PD-L1 were grown under standard conditions, and were plated at 1.25 x 10 4 cells per well and allowed to adhere overnight at 37°C in a humidified 5% C0 2 atmosphere. On the next day, plates were washed with culture media, various concentration of testing antibodies were added to each well, followed by the addition of 3.75 x 10 4 PD-1 -NFAT-luc Jurkat T cells and Ix CytoStim. Plates were covered with a gas permeable seal and incubated at 37°C in a humidified 5% C0 2 atmosphere. After 4h, 30 mI_ Bio-GloTM Reagent was added to each well and the bioluminescent signal was quantified using a luminometer (PHERAstar). Four-parameter logistic curve analysis was performed with GraphPad Prism® to calculate EC 50 values (shared bottom, fixed slope), which are summarized in Table 7. The assay was performed in triplicates.
  • Example 11 Assessment of T cell activation using human peripheral blood mononuclear cells (PBMCs)
  • a T cell assay was employed to assess the ability of exemplary humanized 388D4 to revert the inhibitory signaling of the negative checkpoint molecule PD-1 by blocking the interaction between PD-1 and its ligands.
  • antibodies at different concentrations were added to staphylococcal enterotoxin B (SEB) stimulated human peripheral blood mononuclear cells (PBMCs) and incubated for 4 days at 37°C.
  • SEB staphylococcal enterotoxin B
  • PBMCs peripheral blood mononuclear cells
  • PBMCs from healthy volunteer donors were isolated from buffy coats by centrifugation through a polysucrose density gradient (Biocoll, 1.077 g/mL, Biochrom), following Biochrom ' s protocols.
  • the purified PBMCs were resuspended in a buffer consisting of 90% FCS and 10% DMSO, immediately frozen down using liquid nitrogen and stored in liquid nitrogen until further use.
  • PBMCs were thawed and rested for 16 h in culture media (RPMI 1640, Life Technologies) supplemented with 10% FCS and 1% Penicillin-Streptomycin (Life Technologies).
  • PBMCs 2.5x10 4 PBMCs were incubated in each well of a 384 well flat-bottom tissue culture plates in culture media supplemented or not with SEB at 0.1 ng/mL. Subsequently, a dilution series of the humanized antibodies, benchmark PD-1 antibody, and negative controls typically ranging from 100 to 0.001 nM were added to the cells. Plates were covered with a gas permeable seal and incubated at 37°C in a humidified 5% C0 2 atmosphere for four days. Subsequently, IL-2 levels in the supernatant were assessed.
  • a 384 well plate was coated at room temperature for 2 h with 1 pg/mL“Human IL-2 Capture Antibody” (R&D Systems) in PBS. Subsequently, wells were washed 5 times with 80 pi PBS-0.05%T. After 1 h blocking in PBS-0.05%T additionally containing 1% casein (w/w), pooled supernatants and a concentration series of an IL-2 standard diluted in culture medium was incubated in the 384-well plate overnight at 4°C.
  • R&D Systems Human IL-2 Capture Antibody
  • Example 12 Tumor growth inhibition by humanized antibodies in mouse tumor model
  • HCC827 cells in a matrigel/PBS (1 :1 ) solution Tumors were allowed to grow for 10 days and on day 0 of the experiment mice were randomized into treatment groups according to tumor size and animal weight. Mice were given 5 c 10 6 fresh human PBMC intravenously (i.v.) into a tail vein. Mice received treatment or control into the intraperitoneal cavity after PBMC injection on day 1 , and again on day 4, day 8, and day 12. Tumor growth was recorded every 3-4 days.
  • Figure 8 compares the changes in tumor volumes on day 4, day 8, day 11 , and day 14 of the study. Tumor growth inhibition was achieved by the PD-1-specific antibody SEQ ID NOs: 109 and 1 15.
  • Embodiments illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein.
  • the terms“comprising,”“including,”“containing,” etc. shall be read expansively and without limitation.
  • the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed.
  • Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med , 8, 793-800.
  • PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.
  • TCR T cell receptor
  • IMGT/DomainGapAlign a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF. Nucleic Acids Res, 38, D301-7.
  • ALTSCHUL S. F., MADDEN, T. L, SCHAFFER, A. A., ZHANG, J., ZHANG, Z., MILLER, W. & LIPMAN, D.
  • B7-H1 a third member of the B7 family, co stimulates T-cell proliferation and interleukin-10 secretion. Nat Med, 5, 1365-9.
  • TERME M., ULLRICH, E., AYMERIC, L, MEINHARDT, K., DESBOIS, M., DELAHAYE, N., VIAUD, S., RYFFEL, B., YAGITA, H., KAPLANSKI, G., PREVOST-BLONDEL, A., KATO, M., SCHULTZE, J. L, TARTOUR, E., KROEMER, G., CHAPUT, N. & ZITVOGEL, L. 2011. IL-18 induces PD-l-dependent immunosuppression in cancer. Cancer Res, 71, 5393-9.
  • NISHIMURA H., OKAZAKI, T., TANAKA, Y., NAKATANI, K., HARA, M., MATSUMORI, A., SASAYAMA, S., MIZOGUCHI, A., HIAI, H., MINATO, N. & HONJO, T. 2001.
  • NISHIMURA H., NOSE, M., HIAI, H., MINATO, N. & HONJO, T. 1999. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity, 11, 141-51.
  • HAMID O., ROBERT, C., DAUD, A., HODI, F. S., HWU, W. J., KEFFORD, R., WOLCHOK, J. D., HERSEY, P., JOSEPH, R. W., WEBER, J. S., DRONCA, R., GANGADHAR, T. C., PATNAIK, A., ZAROUR, H., JOSHUA, A. M., GERGICH, K., ELASSAISS-SCHAAP, J., ALGAZI, A., MATEUS, C., BOASBERG, P., TUMEH, P.
  • the S228P mutation prevents in vivo and in vitro lgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation.
  • J Biol Chem, 290, 5462-9. GLAESNER, W., VICK, A. M., MILLICAN, R., ELLIS, B., TSCHANG, S. H., TIAN, Y., BOKVIST, K., BRENNER, M., KOESTER, A., PORKSEN, N., ETGEN, G. & BUMOL, T. 2010.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne, entre autres, des anticorps humanisés qui se lient à la protéine 1 de mort cellulaire programmée (PD-1) et des compositions comprenant de tels anticorps, les anticorps et/ou les compositions pouvant être utiles pour générer une réponse anti-tumeur ou anti-infection durable. De tels anticorps peuvent être utilisés dans de nombreuses utilisations pharmaceutiques, par exemple, à titre d'agent anticancéreux et/ou de modulateurs immunitaires pour traiter ou prévenir des maladies humaines telles que diverses tumeurs, ou à titre d'agent anti-infectieux. La présente invention concerne également des procédés de préparation des anticorps selon l'invention ainsi que des compositions comprenant lesdits anticorps. La présente invention concerne en outre des molécules d'acide nucléique codant pour de tels anticorps et des procédés de production de ces anticorps et molécules d'acide nucléique. De plus, l'invention concerne des utilisations thérapeutiques et/ou diagnostiques de ces anticorps ainsi que des compositions comprenant un ou plusieurs de ces anticorps.
PCT/EP2019/070171 2018-07-26 2019-07-26 Anticorps humanisés anti-pd-1 et leurs utilisations Ceased WO2020021061A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18185649.3 2018-07-26
EP18185649 2018-07-26

Publications (1)

Publication Number Publication Date
WO2020021061A1 true WO2020021061A1 (fr) 2020-01-30

Family

ID=63077705

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/070171 Ceased WO2020021061A1 (fr) 2018-07-26 2019-07-26 Anticorps humanisés anti-pd-1 et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2020021061A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113372445A (zh) * 2020-03-10 2021-09-10 鲁南制药集团股份有限公司 一种抗pd-1单克隆抗体
WO2024023246A1 (fr) * 2022-07-28 2024-02-01 Philogen S.P.A. Anticorps se liant à pd1
EP4293046A4 (fr) * 2021-02-10 2025-03-05 Shanghai Jemincare Pharmaceuticals Co., Ltd. Anticorps anti-pd-1 et son utilisation

Citations (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4301144A (en) 1979-07-11 1981-11-17 Ajinomoto Company, Incorporated Blood substitute containing modified hemoglobin
US4495285A (en) 1981-10-30 1985-01-22 Kimihiro Shimizu Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4670417A (en) 1985-06-19 1987-06-02 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
EP0404097A2 (fr) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Récepteurs mono- et oligovalents, bispécifiques et oligospécifiques, ainsi que leur production et application
WO1993011161A1 (fr) 1991-11-25 1993-06-10 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6054297A (en) 1991-06-14 2000-04-25 Genentech, Inc. Humanized antibodies and methods for making them
US20030039653A1 (en) 2001-04-20 2003-02-27 Lieping Chen Methods of enhancing T cell responsiveness
WO2003099196A2 (fr) 2002-05-23 2003-12-04 Cure Tech Ltd. Anticorps monoclonaux humanises immunomodulateurs servant a traiter une maladie neoplasique ou une immunodeficience
US20040213795A1 (en) 2002-12-23 2004-10-28 Wyeth Antibodies against PD-1 and uses therefor
US6982321B2 (en) 1986-03-27 2006-01-03 Medical Research Council Altered antibodies
US20060110383A1 (en) 2002-07-03 2006-05-25 Tasuku Honjo Immunopotentiative composition
WO2006121168A1 (fr) 2005-05-09 2006-11-16 Ono Pharmaceutical Co., Ltd. Anticorps monoclonaux humains pour mort programmee 1 (mp-1) et procedes pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associes a d’autres immunotherapies
WO2007005874A2 (fr) 2005-07-01 2007-01-11 Medarex, Inc. Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
US20070065427A1 (en) 2001-11-13 2007-03-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
US20070122378A1 (en) 2005-06-08 2007-05-31 Gordon Freeman Methods and compositions for the treatment of persistent infections
WO2008156712A1 (fr) 2007-06-18 2008-12-24 N. V. Organon Anticorps dirigés contre le récepteur humain de mort programmée pd-1
WO2009114335A2 (fr) 2008-03-12 2009-09-17 Merck & Co., Inc. Protéines de liaison avec pd-1
WO2010027423A2 (fr) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions d'antagonistes de pd-1 et methodes d'utilisation associees
WO2011110604A1 (fr) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Anticorps pd-1
WO2012145493A1 (fr) 2011-04-20 2012-10-26 Amplimmune, Inc. Anticorps et autres molécules qui se lient à b7-h1 et à pd-1
WO2013014668A1 (fr) 2011-07-24 2013-01-31 Curetech Ltd. Variants d'anticorps monoclonaux immunomodulateurs humanisés
WO2014194302A2 (fr) 2013-05-31 2014-12-04 Sorrento Therapeutics, Inc. Protéines de liaison à l'antigène qui se lient à pd-1
WO2015035606A1 (fr) 2013-09-13 2015-03-19 Beigene, Ltd. Anticorps anti-pd1 et leur utilisation comme produits thérapeutiques et produits de diagnostic
US20150203579A1 (en) 2014-01-23 2015-07-23 Regeneron Pharmaceuticals, Inc. Human Antibodies to PD-1
WO2016102716A1 (fr) 2014-12-24 2016-06-30 Pierre Fabre Medicament Nouveaux anticorps anti-adam17 humanisés
WO2016106159A1 (fr) 2014-12-22 2016-06-30 Enumeral Biomedical Holding, Inc. Anticorps anti-pd-1
WO2017025498A1 (fr) * 2015-08-07 2017-02-16 Pieris Pharmaceuticals Gmbh Nouveau polypeptide de fusion spécifique de lag-3 et pd-1
US20170044259A1 (en) * 2015-07-13 2017-02-16 Cytomx Therapeutics, Inc. Anti-pd1 antibodies, activatable anti-pd1 antibodies, and methods of use thereof
WO2017055443A1 (fr) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anticorps anti-pd1 et méthodes d'utilisation
WO2018134279A1 (fr) * 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Nouveaux polypeptides de fusion spécifiques de lag-3 et pd-1

Patent Citations (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4301144A (en) 1979-07-11 1981-11-17 Ajinomoto Company, Incorporated Blood substitute containing modified hemoglobin
US4495285A (en) 1981-10-30 1985-01-22 Kimihiro Shimizu Plasminogen activator derivatives
US4495285B1 (fr) 1981-10-30 1986-09-23 Nippon Chemiphar Co
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4670417A (en) 1985-06-19 1987-06-02 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US6982321B2 (en) 1986-03-27 2006-01-03 Medical Research Council Altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6180370B1 (en) 1988-12-28 2001-01-30 Protein Design Labs, Inc. Humanized immunoglobulins and methods of making the same
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
US5693761A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Polynucleotides encoding improved humanized immunoglobulins
US5693762A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7022500B1 (en) 1988-12-28 2006-04-04 Protein Design Labs, Inc. Humanized immunoglobulins
EP0404097A2 (fr) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Récepteurs mono- et oligovalents, bispécifiques et oligospécifiques, ainsi que leur production et application
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6054297A (en) 1991-06-14 2000-04-25 Genentech, Inc. Humanized antibodies and methods for making them
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011161A1 (fr) 1991-11-25 1993-06-10 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US20030039653A1 (en) 2001-04-20 2003-02-27 Lieping Chen Methods of enhancing T cell responsiveness
US20070065427A1 (en) 2001-11-13 2007-03-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
WO2003099196A2 (fr) 2002-05-23 2003-12-04 Cure Tech Ltd. Anticorps monoclonaux humanises immunomodulateurs servant a traiter une maladie neoplasique ou une immunodeficience
US20060110383A1 (en) 2002-07-03 2006-05-25 Tasuku Honjo Immunopotentiative composition
US20040213795A1 (en) 2002-12-23 2004-10-28 Wyeth Antibodies against PD-1 and uses therefor
WO2006121168A1 (fr) 2005-05-09 2006-11-16 Ono Pharmaceutical Co., Ltd. Anticorps monoclonaux humains pour mort programmee 1 (mp-1) et procedes pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associes a d’autres immunotherapies
US20090217401A1 (en) 2005-05-09 2009-08-27 Medarex, Inc Human Monoclonal Antibodies To Programmed Death 1(PD-1) And Methods For Treating Cancer Using Anti-PD-1 Antibodies Alone or in Combination with Other Immunotherapeutics
US20070122378A1 (en) 2005-06-08 2007-05-31 Gordon Freeman Methods and compositions for the treatment of persistent infections
WO2007005874A2 (fr) 2005-07-01 2007-01-11 Medarex, Inc. Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
WO2008156712A1 (fr) 2007-06-18 2008-12-24 N. V. Organon Anticorps dirigés contre le récepteur humain de mort programmée pd-1
WO2009114335A2 (fr) 2008-03-12 2009-09-17 Merck & Co., Inc. Protéines de liaison avec pd-1
US20110008369A1 (en) 2008-03-12 2011-01-13 Finnefrock Adam C Pd-1 binding proteins
WO2010027423A2 (fr) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions d'antagonistes de pd-1 et methodes d'utilisation associees
WO2011110604A1 (fr) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Anticorps pd-1
WO2012145493A1 (fr) 2011-04-20 2012-10-26 Amplimmune, Inc. Anticorps et autres molécules qui se lient à b7-h1 et à pd-1
WO2013014668A1 (fr) 2011-07-24 2013-01-31 Curetech Ltd. Variants d'anticorps monoclonaux immunomodulateurs humanisés
WO2014194302A2 (fr) 2013-05-31 2014-12-04 Sorrento Therapeutics, Inc. Protéines de liaison à l'antigène qui se lient à pd-1
WO2015035606A1 (fr) 2013-09-13 2015-03-19 Beigene, Ltd. Anticorps anti-pd1 et leur utilisation comme produits thérapeutiques et produits de diagnostic
US20150203579A1 (en) 2014-01-23 2015-07-23 Regeneron Pharmaceuticals, Inc. Human Antibodies to PD-1
WO2016106159A1 (fr) 2014-12-22 2016-06-30 Enumeral Biomedical Holding, Inc. Anticorps anti-pd-1
WO2016102716A1 (fr) 2014-12-24 2016-06-30 Pierre Fabre Medicament Nouveaux anticorps anti-adam17 humanisés
US20170044259A1 (en) * 2015-07-13 2017-02-16 Cytomx Therapeutics, Inc. Anti-pd1 antibodies, activatable anti-pd1 antibodies, and methods of use thereof
WO2017025498A1 (fr) * 2015-08-07 2017-02-16 Pieris Pharmaceuticals Gmbh Nouveau polypeptide de fusion spécifique de lag-3 et pd-1
WO2017055443A1 (fr) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anticorps anti-pd1 et méthodes d'utilisation
WO2018134279A1 (fr) * 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Nouveaux polypeptides de fusion spécifiques de lag-3 et pd-1

Non-Patent Citations (46)

* Cited by examiner, † Cited by third party
Title
"UniProt", Database accession no. Q15116
ALAVIJEH, M. S.PALMER, A. M.: "The pivotal role of drug metabolism and pharmacokinetics in the discovery and development of new medicines", IDRUGS, vol. 7, 2004, pages 755 - 63
ALMAGRO, J. C.FRANSSON, J.: "Humanization of antibodies", FRONT BIOSCI, vol. 13, 2008, pages 1619 - 33
ALTSCHUL, S. F.GISH, W.MILLER, W.MYERS, E. W.LIPMAN, D. J.: "Basic local alignment search tool", J MOL BIOL, vol. 215, 1990, pages 403 - 10, XP002949123, DOI: doi:10.1006/jmbi.1990.9999
ALTSCHUL, S. F.MADDEN, T. L.SCHAFFER, A. A.ZHANG, J.ZHANG, Z.MILLER, W.LIPMAN, D. J.: "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", NUCLEIC ACIDS RES, vol. 25, 1997, pages 3389 - 402, XP002905950, DOI: doi:10.1093/nar/25.17.3389
AUSUBEL, F. M.: "Short protocols in molecular biology: a compendium of methods from Current protocols in molecular biology,", 1992, GREENE PUB. ASSOCIATES; WILEY
BLANK, C.BROWN, I.PETERSON, A. C.SPIOTTO, M.IWAI, Y.HONJO, T.GAJEWSKI, T. F.: "PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells", CANCER RES, vol. 64, 2004, pages 1140 - 5, XP009076235, DOI: doi:10.1158/0008-5472.CAN-03-3259
CARTER ET AL., PROC NATL ACAD SCI U S A, 1992
CARTER, P.PRESTA, LGORMAN, C. M.RIDGWAY, J. B.HENNER, D.WONG, W. L.ROWLAND, A. M.KOTTS, C.CARVER, M. E.SHEPARD, H. M.: "Humanization of an anti-p185HER2 antibody for human cancer therapy", PROC NATL ACAD SCI USA, vol. 89, 1992, pages 4285 - 9, XP055124497
CHOTHIA, C.LESK, A. M.: "Canonical structures for the hypervariable regions of immunoglobulins", J MOL BIOL, vol. 196, 1987, pages 901 - 17, XP024010426, DOI: doi:10.1016/0022-2836(87)90412-8
DALL'ACQUA, W. F.KIENER, P. A.WU, H.: "Properties of human IgGls engineered for enhanced binding to the neonatal Fc receptor (FcRn", J BIOL CHEM, vol. 281, 2006, pages 23514 - 24, XP002404904, DOI: doi:10.1074/jbc.M604292200
DONG, H.STROME, S. E.SALOMAO, D. R.TAMURA, H.HIRANO, F.FLIES, D. B.ROCHE, P. C.LU, J.ZHU, G.TAMADA, K.: "Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion", NAT MED, vol. 8, 2002, pages 793 - 800, XP002397368, DOI: doi:10.1038/nm730
DONG, H.ZHU, G.TAMADA, K.CHEN, L.: "B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion", NAT MED, vol. 5, 1999, pages 1365 - 9, XP055204019, DOI: doi:10.1038/70932
EHRENMANN, F.KAAS, Q.LEFRANC, M. P.: "IMGT/3Dstructure-DB and IMGT/DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF", NUCLEIC ACIDS RES, vol. 38, 2010, pages D301 - 7, XP055247165, DOI: doi:10.1093/nar/gkp946
GALON, J.COSTES, A.SANCHEZ-CABO, F.KIRILOVSKY, A.MLECNIK, B.LAGORCE-PAGES, C.TOSOLINI, M.CAMUS, M.BERGER, A.WIND, P.: "Type, density, and location of immune cells within human colorectal tumors predict clinical outcome", SCIENCE, vol. 313, 2006, pages 1960 - 4, XP002684010, DOI: doi:10.1126/SCIENCE.1129139
GLAESNER, W.VICK, A. M.MILLICAN, R.ELLIS, B.TSCHANG, S. H.TIAN, Y.BOKVIST, K.BRENNER, M.KOESTER, A.PORKSEN, N.: "Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein", DIABETES METAB RES REV, vol. 26, 2010, pages 287 - 96, XP055181624, DOI: doi:10.1002/dmrr.1080
GREENWALD, R. J.FREEMAN, G. J.SHARPE, A. H.: "The B7 family revisited", ANNU REV IMMUNOL, vol. 23, 2005, pages 515 - 48, XP002481408, DOI: doi:10.1146/annurev.immunol.23.021704.115611
HAMANISHI ET AL., PROC NATL ACAD SCI U S A, 2007
HAMANISHI, J.MANDAI, M.IWASAKI, M.OKAZAKI, T.TANAKA, Y.YAMAGUCHI, K.HIGUCHI, T.YAGI, H.TAKAKURA, K.MINATO, N.: "Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer", PROC NATL ACAD SCI USA, vol. 104, 2007, pages 3360 - 5
HAMID, O.ROBERT, C.DAUD, A.HODI, F. S.HWU, W. J.KEFFORD, R.WOLCHOK, J. D.HERSEY, P.JOSEPH, R. W.WEBER, J. S.: "Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma", N ENGL J MED, vol. 369, 2013, pages 134 - 44, XP055182016, DOI: doi:10.1056/NEJMoa1305133
HIRANO, F.KANEKO, K.TAMURA, H.DONG, H.WANG, S.ICHIKAWA, M.RIETZ, C.FLIES, D. B.LAU, J. S.ZHU, G.: "Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity", CANCER RES, vol. 65, 2005, pages 1089 - 96, XP002419626
HOLLIGER ET AL., PROC NATL ACAD SCI U S A, 1993
HOLLIGER, P.PROSPERO, T.WINTER, G.: "Diabodies'': small bivalent and bispecific antibody fragments", PROC NATL ACAD SCI USA, vol. 90, 1993, pages 6444 - 8, XP002008022, DOI: doi:10.1073/pnas.90.14.6444
IGAWA, T.TSUNODA, H.KURAMOCHI, T.SAMPEI, Z.ISHII, S.HATTORI, K.: "Engineering the variable region of therapeutic IgG antibodies", MABS, vol. 3, 2011, pages 243 - 52, XP055532830, DOI: doi:10.4161/mabs.3.3.15234
IWAI, Y.TERAWAKI, S.HONJO, T.: "PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells", INT IMMUNOL, vol. 17, 2005, pages 133 - 44, XP055142463, DOI: doi:10.1093/intimm/dxh194
JOHNSON, G.WU, T. T.: "Kabat database and its applications: 30 years after the first variability plot", NUCLEIC ACIDS RES, vol. 28, 2000, pages 214 - 8, XP009132432
KEIR, M. E.BUTTE, M. J.FREEMAN, G. J.SHARPE, A. H.: "PD-1 and its ligands in tolerance and immunity", ANNU REV IMMUNOL, vol. 26, 2008, pages 677 - 704, XP055099324, DOI: doi:10.1146/annurev.immunol.26.021607.090331
LEFRANC, M. P.: "The IMGT unique numbering for immunoglobulins, T-cell receptors, and Ig-like domains", IMMUNOLOGIST, vol. 7, 1999, pages 132 - 136
M. SZNOL ET AL: "Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer", CLINICAL CANCER RESEARCH, vol. 19, no. 5, 1 March 2013 (2013-03-01), pages 1021 - 1034, XP055123957, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-12-2063 *
NISHIMURA, H.NOSE, M.HIAI, H.MINATO, NHONJO, T.: "Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor", IMMUNITY, vol. 11, 1999, pages 141 - 51, XP000971788, DOI: doi:10.1016/S1074-7613(00)80089-8
NISHIMURA, H.OKAZAKI, T.TANAKA, Y.NAKATANI, K.HARA, M.MATSUMORI, A.SASAYAMA, S.MIZOGUCHI, A.HIAI, H.MINATO, N.: "Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice", SCIENCE, vol. 291, 2001, pages 319 - 22
PARDOLL, D. M.: "The blockade of immune checkpoints in cancer immunotherapy", NAT REV CANCER, vol. 12, 2012, pages 252 - 64, XP055415943, DOI: doi:10.1038/nrc3239
PARRY, R. V.CHEMNITZ, J. M.FRAUWIRTH, K. A.LANFRANCO, A. R.BRAUNSTEIN, I.KOBAYASHI, S. V.LINSLEY, P. S.THOMPSON, C. B.RILEY, J. L.: "CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms", MOL CELL BIOL, vol. 25, 2005, pages 9543 - 53, XP003026807, DOI: doi:10.1128/MCB.25.21.9543-9553.2005
PRESTA, L. G.LAHR, S. J.SHIELDS, R. L.PORTER, J. P.GORMAN, C. M.FENDLY, B. M.JARDIEU, P. M.: "Humanization of an antibody directed against IgE", J IMMUNOL, vol. 151, 1993, pages 2623 - 32
RYMAN, J. T.MEIBOHM, B.: "Pharmacokinetics of Monoclonal Antibodies", CPT PHARMACOMETRICS SYST PHARMACOL, vol. 6, 2017, pages 576 - 588
SAMBROOK, J.RUSSELL, D. W.: "Molecular cloning : a laboratory manual", 2001, COLD SPRING HARBOR LABORATORY PRESS
SHARPE, A. H.WHERRY, E. J.AHMED, R.FREEMAN, G. J.: "The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection", NAT IMMUNOL, vol. 8, 2007, pages 239 - 45
SILVA, J. P.VETTERLEIN, O.JOSE, J.PETERS, S.KIRBY, H.: "The S228P mutation prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation", J BIOL CHEM, vol. 290, 2015, pages 5462 - 9, XP055299482, DOI: doi:10.1074/jbc.M114.600973
SIMS, M. JHASSAL, D. G.BRETT, S.ROWAN, W.LOCKYER, M. J.ANGEL, A.LEWIS, A. P.HALE, G.WALDMANN, H.CROWE, J. S.: "A Humanized Cdl8 Antibody Can Block Function without Cell Destruction", J IMMUNOL, vol. 151, 1993, pages 2296 - 2308
SMITH, T. F.WATERMAN, M. S.: "Identification of common molecular subsequences", J MOL BIOL, vol. 147, 1981, pages 195 - 7, XP024015032, DOI: doi:10.1016/0022-2836(81)90087-5
TERME, M.ULLRICH, E.AYMERIC, L.MEINHARDT, K.DESBOIS, M.DELAHAYE, N.VIAUD, S.RYFFEL, B.YAGITA, H.KAPLANSKI, G.: "IL-18 induces PD-1-dependent immunosuppression in cancer", CANCER RES, vol. 71, 2011, pages 5393 - 9
TILMAN SCHLOTHAUER ET AL: "Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions", PROTEIN ENGINEERING, DESIGN AND SELECTION, vol. 29, no. 10, 29 August 2016 (2016-08-29), GB, pages 457 - 466, XP055414310, ISSN: 1741-0126, DOI: 10.1093/protein/gzw040 *
TOPALIAN, S. L.HODI, F. S.BRAHMER, J. R.GETTINGER, S. N.SMITH, D. C.MCDERMOTT, D. F.POWDERLY, J. D.CARVAJAL, R. D.SOSMAN, J. A.ATK: "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", N ENGL J MED, vol. 366, 2012, pages 2443 - 54, XP055098235, DOI: doi:10.1056/NEJMoa1200690
WARD, E. S.GUSSOW, D.GRIFFITHS, A. D.JONES, P. T.WINTER, G.: "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli", NATURE, vol. 341, 1989, pages 544 - 6
ZALEVSKY, J.CHAMBERLAIN, A. K.HORTON, H. M.KARKI, S.LEUNG, I. W.SPROULE, T. J.LAZAR, G. A.ROOPENIAN, D. C.DESJARLAIS, J. R.: "Enhanced antibody half-life improves in vivo activity", NAT BIOTECHNOL, vol. 28, 2010, pages 157 - 9, XP055308991, DOI: doi:10.1038/nbt.1601
ZHANG TONG ET AL: "The binding of an anti-PD-1 antibody to Fc[gamma]R[Iota] has a profound impact on its biological functions", CANCER IMMUNOLOGY, IMMUNOTHERAPY, NIH AUTHOR MANUSCRIPT, SPRINGER, BERLIN/HEIDELBERG, vol. 67, no. 7, 23 April 2018 (2018-04-23), pages 1079 - 1090, XP036529047, ISSN: 0340-7004, [retrieved on 20180423], DOI: 10.1007/S00262-018-2160-X *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113372445A (zh) * 2020-03-10 2021-09-10 鲁南制药集团股份有限公司 一种抗pd-1单克隆抗体
CN113372445B (zh) * 2020-03-10 2023-09-12 鲁南制药集团股份有限公司 一种抗pd-1单克隆抗体
EP4293046A4 (fr) * 2021-02-10 2025-03-05 Shanghai Jemincare Pharmaceuticals Co., Ltd. Anticorps anti-pd-1 et son utilisation
WO2024023246A1 (fr) * 2022-07-28 2024-02-01 Philogen S.P.A. Anticorps se liant à pd1

Similar Documents

Publication Publication Date Title
KR102522693B1 (ko) 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체
JP7442443B2 (ja) 多重特異性抗体
US11746148B2 (en) Antibody molecules comprising a single-domain antigen-binding site and Fab fragments
KR102907326B1 (ko) Cd137을 표적화하는 항체 및 이의 사용 방법
EP3470426A1 (fr) Anticorps multi-spécifique
CN114685665B (zh) 抗ox40的全人抗体及其制备方法和用途
JP2025111661A (ja) 二重特異性抗体およびその使用
CN112533950A (zh) 抗CD3e抗体及其用途
AU2018348430A1 (en) Antibodies targeting PDL1 and methods of use thereof
JP2025020172A (ja) Ｃｄ１３７を標的とする抗体およびその使用方法
WO2020021061A1 (fr) Anticorps humanisés anti-pd-1 et leurs utilisations
EP3470429A1 (fr) Anticorps dirigés contre pdl1 et leurs procédés d'utilisation
EP3636320A1 (fr) Anticorps dirigés contre cd137 et leurs procédés d'utilisation
WO2025113640A1 (fr) Anticorps se liant à lilrb1/2 ou pd1-lilrb1/2 et son utilisation
CN120813377A (zh) Btn3a活化抗体和免疫检查点抑制剂的组合

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19742771

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19742771

Country of ref document: EP

Kind code of ref document: A1